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THE DEVELOPMENT OF AN ELISA FOR THE QUANTIFICATION OF 
ANTIBODIES AGAINST CD52G, A SPERM COATING GLYCOPROTEIN, IN 
THE SERA OF PATIENTS WITH INFERTILITY  
CLAIRE E. MARCUS 
ABSTRACT 
Antisperm antibodies (ASA) are thought to be a predominate cause of immune 
infertility by interfering with various aspects of sperm function in both the male and the 
female reproductive tracts. The precise mechanism by which these antibodies contribute 
to infertility, as well as their etiology, remains to be established. ASA are present in a 
variety of biological substrates, such as genital tract secretions, and the blood sera of both 
males and females. Although not all ASA underly infertility, a substantial body of 
research suggests that certain ASA, referred to as sperm immobilizing antibodies (SI-
Abs) and sperm agglutinating antibodies, significantly impair sperm transportation in the 
female reproductive tract. High titers of sperm agglutinating or sperm immobilizing 
antibodies have been associated with reproductive failure. CD52g is a GPI anchored 
glycoprotein found on mature sperm and in seminal plasma (SP). Antibodies against a 
male reproductive tract-specific epitope of CD52g are known to readily agglutinate 
sperm. The current study sought to develop an ELISA to quantify the prevalence of 
CD52g antibodies in the sera of male and female patients with infertility, and to 
determine if there was a correlation between the prevalence of CD52g antibodies and the 
prevalence of sperm agglutinating antibodies in the sera of these patients. Ultimately, 
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CD52g antibodies were only detected in the sera of patients (21%) with sperm 
agglutinating antibodies. While detecting CD52g antibodies in sera via an ELISA proved 
challenging, the results of this study corroborate research demonstrating that CD52g 
antibodies have a remarkable capacity to agglutinate sperm. Elucidation of the 
mechanisms underlying this immune response would advance our understanding of 
immune modulation in human reproductive tracts, further the diagnosis of immune 
infertility, and are currently providing the basis for the development of a potent dual 
purpose immunocontraceptive, that both prevents unintended pregnancy, and prevents the 
transmission of sexually transmitted infections (STIs).   
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The World Health Organization (WHO) defines infertility as “a disease of the 
reproductive tract characterized by the failure to achieve pregnancy after 12 months or 
more, of regular, unprotected, sexual intercourse” [1]. Infertility, a critical component of 
reproductive health, is a remarkably prevalent health condition. Worldwide, an estimated 
8-12% of reproductive-age couples are infertile [2], with countries in Eastern Europe, 
North Africa/Middle East, Oceania, and Sub-Saharan Africa having the highest 
prevalence of infertility [3]. Males are found to be solely responsible for 20-30% of 
infertility cases [2]. Semen analysis, the evaluation of semen volume, sperm count, 
motility, and morphology, has been the chief means of diagnosing male factor infertility 
since the 1930s [4]. Infertility is attributed to ovulatory defects in 40% of infertile women 
and evaluation of such defects can involve the detection of hormonal indicators of 
ovulation, assessment of ovarian reserve, and radiographic evaluation of the uterine 
cavity and fallopian tubes [5]. If the results of the aforementioned tests fail to reveal 
marked abnormalities, a diagnosis of exclusion is reached, and the couple’s infertility is 
described as “unexplained” [5]. Approximately 15-30% of infertile couples will be 
diagnosed with unexplained infertility (UI) [5]. The etiology of UI remains diffuse, with 
research suggesting that a complex interplay of aberrant endocrine, genetic, 
immunological and physiological mechanisms may be responsible [5].  
The influence of immune mechanisms in the pathogenesis of unexplained 
infertility has been the subject of investigation since 1899, when “spermotoxic” 
antibodies in rabbits sensitized with bull semen were first found to immobilized sperm 
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cells [6]. In 1922, Dr. Samuel Meaker first documented the presence of antisperm 
antibodies (ASA) in women [7]. In humans, Rosenfled first surmised that immunizing 
women with human semen could lead to infertility [8]. Baskin subsequently turn these 
ideas into reality [9] and patented a “spermotoxic vaccine” in 1937 [10].  By 1954 
Rumpke and Wilson independently demonstrated that antisperm antibodies were 
associated with male infertility [11,12]. Although research into ASA was eclipsed by the 
development of assisted reproductive technologies (ART) [13], fascinating questions 
concerning the dynamic role ASA play in reproductive biology remains especially 
relevant. Understanding the extent to which ASA impair not only sperm transport but 
directly interfere with sperm/oocyte interaction, could potentially help physicians choose 
the least aggressive, and most effective, intervention for patients seeking to achieve a 
pregnancy [14]. The identification of cognate antigens of ASA that impede fertilization 
could be used as targets for immune contraception [14]. The characterization of ASA and 
their cognate antigens provides a route by which to not only more thoroughly understand 
the molecular pathways underlying fertilization, but to also unravel the intricate immune 
mechanisms involved in establishing and maintaining pregnancy.   
One sperm antigen potentially relevant to immune infertility is the glycoprotein 
CD52g. CD52g is found abundantly in the male reproductive tract, including mature 
sperm and seminal plasma (SP) [15]. Antibodies raised against CD52g have been shown 
to readily immobilize and agglutinate sperm [15]. Bronson et al. established a serum 
repository from patients with infertility and determined the subclass and incidence of 
ASA in each serum sample. The Anderson Lab obtained aliquots of the sera from the 
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repository and subsequently determined the degree to which each patients’ serum 
agglutinated sperm. The objectives of the current study were to determine the prevalence 
of antibodies directed against CD52g in the sera and to determine if the prevalence of 
agglutinating antibodies in the sera correlated with that of CD52g antibodies. If there was 
a marked increase in the prevalence of CD52g antibodies in the serum of infertility 
patients, as compared to controls, and these serum samples exhibited a strong capacity to 
agglutinate sperm, this would corroborate decades of research suggesting that ASA, 
against antigens essential to sperm functioning, play a pivotal role in alloimmune 
challenges to human fertilization, and add further credence to the supposition that one 















CHAPTER 1. LITERATURE REVIEW OF ANTISPERM ANTIBODIES (ASA) 
The development of ASA is a fascinating immunological phenomenon that has not been 
clearly elucidated. However, theories on the nature of ASA reactions have been posited, 
which seek to reconcile the many discrepancies and complexities that arise in the study of 
these curious proteins.   
1.1 NATURAL AUTOANTIBODIES 
Natural autoantibodies (NAA), or natural antibodies (NAb), are a collection of 
spontaneously secreted antibodies that are surprisingly difficult to define [16]. In its 
purest form, NAA are defined as polyreactive, germline-like (no N-additions and little 
somatic hypermutation), low affinity antibodies, generated in the absence of foreign 
antigen (though their production is influenced by them), and without helper T cells, that 
recognize both self-antigen and foreign pathogens [16,17]. In mice, NAA are 
predominantly generated by a subset of B-1 cells (B-1a or CD5+ B-1 cells). B-1a cells 
principally secrete IgM-NAA, but also IgA-NAA and IgG-NAA (mostly IgG3) [17]. 
Although there are significant challenges in discerning all the particular B cells types 
capable of secreting NAA in humans [16-18], the human equivalent of B-1a cells has 
been identified and represents 15-20% of circulating adult B cells [19]. Research 
concerning the physiological role of NAA, particularly IgM-NAA, has illuminated just 
how essential NAA are to modulating immune responses and protecting humans from 
infectious and autoimmune diseases. IgM-NAA combat invading pathogens until the 
sluggish B2 and T cells are deployed and hinders both the production, and machinations, 
of pathogenic IgG autoantibodies [17-19]. IgM-NAA can bind to a limited range of 
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highly conserved epitopes found in self-antigens and thereby hide them from pathogenic 
autoantibodies or induce the clearance of dead or senescent somatic cells [17,19]. 
Furthermore, IgM-NAA can bind to receptors on leukocytes including T cells, dendritic 
cells, and B-1 cells to modulate their activities and/or development [17]. 
The sperm surface is coated by a complex array of carbohydrate, lipid, and 
protein specificities that have been conserved over evolution [21], and as such, are prime 
targets for NAA. Essentially, sperm surface carbohydrates may serve to stimulate the 
production of NAA and thereby mask integral sperm antigens from immune surveillance 
[15]. Paradisi et al. reported on several interesting phenomena in this regard. Previous 
research has shown that antisperm antibodies are present in both fertile and infertile 
populations, although the prevalence of ASA in these populations varies depending on 
the assay utilized. ASA have been found in 10% of infertile men and 5% of infertile 
women [22]. However, they have also been detected in 1-2.5% of fertile men and 4% of 
fertile women [22]. Paradisi et al. theorized that sperm antigens should be classified into 
three groups or types: (1) antigens recognized by natural autoantibodies or cross-reactive 
antibodies (a product of molecular mimicry) that are functionally irrelevant and are 
present in both fertile and infertile populations, (2) antigens present only in infertile 
populations and pathogenic in nature, (3) antigens belonging to the first category that can 
elicit a heighted immune response, perhaps due to a breakdown in immune tolerance 
[23].  
A strain of research that testifies to the significance of natural autoantibodies 
against sperm, concerns antisperm antibodies developed before puberty. Tung et al. 
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demonstrated that ASA reached their peak incidence in both boys and girls at ages 1-10 
before puberty and thus before mechanisms of immunological tolerance are established 
[24]. They suspect that either molecular mimicry to microorganisms with similar 
epitopes, antigenic leak, and natural autoantibodies all may be potentially responsible for 
this phenomenon [24]. Furthermore, fascinating research by Flickinger et al. showed an 
increase in serum antisperm autoantibodies (including IgG autoantibodies) once Lewis 
rats reached puberty [25]. Flickinger et al. reasoned that as germ cells entered new stages 
of development and sperm neo-antigens arose, so too did an autoantibody response to 
sperm [25]. They remark that dynamic yet tightly regulated immune mechanisms to 
suppress orchitis must be operating. Paradisi et al.’s suggestion of a third category of 
sperm antigens composed of those that are initially recognized by NAA but subsequently 
evoke a more aggressive immune response is significant, as CD52g may belong in this 
third category of sperm antigens. Its core peptide, CD52, is found on a host of somatic 
cells while the glycosylated isoform is found on sperm cells [15]. It is possible that in the 
context of a particular inflammatory condition, the glycosylated isoform could induce an 
enhanced reactivity by natural autoantibodies [6,15,23]. The enhancement of a natural, 
physiological autoantibody response to a pathological level, in response to elevated levels 
of autoantigen, due to either a breakdown in tolerance and/or molecular mimicry 
following infection, could explain the existence of ASA in healthy pre-pubescent children 





1.2 ANTISPERM ANTIBODIES AND MALE INFERILITY  
At puberty, spermatogenesis coincides the formation of the blood testis barrier-a 
nearly impenetrable barricade, composed of various types of junctional proteins, that 
divides the seminiferous epithelium into two distinct compartments (basal and abluminal) 
[26]. The blood testis barrier was once thought to be solely responsible for preventing an 
immune response to self-antigens and alloantigens in the testis [26]. However, immune 
privilege in the testis is now a more complex and colorful picture. The blood testis barrier 
is still central to limiting immune activity in the abluminal compartment, but other 
mechanisms including the muted pro-inflammatory activity and the immunosuppressive 
character of testicular macrophages, immature testicular dendritic cells, and a propensity 
for the programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) system 
to thwart any self-reactive T cells in the testis, all underly testicular immune privilege 
[27]. Furthermore, there is significant immune suppression by Sertoli cells and Leydig 
cells. For instance, Sertoli cells are efficient phagocytes of approximately half of the 
testicular germinal cells that undergo apoptosis, thereby helping to prevent an immune 
response to neo-antigens that arise as these germ cells further mature and/or die [28].  
Seminal plasma (SP) provides not only transportation and nutrition to 
spermatozoa but also limits immune responses as spermatozoa mature in the testis and 
journey through the female reproductive tract [29]. Seminal plasma is a complex mixture 
of diverse biomolecules, derived from secretions from the testes, epididymides, prostate, 
seminal vesicles, and bulbourethral glands [30]. It is composed of an array of 
immunosuppressive substances that prevent autoimmune responses to sperm antigens. 
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Seminal plasma contains an abundance of prostaglandins, notably PGE2, which inhibits 
or restricts the activity of neutrophils, macrophages, natural killer cells, CD 8+ T cells, 
and T Helper type 1 responses [31]. Soluble Fc receptors, numerous regulators of the 
complement system, and lactoferrin-an invaluable weapon and modulator of immunity 
[32] are just a few of the many modulators of inflammation which constitute seminal 
plasma. The activities of all of these macromolecules, as well as a host of others, creates 
a milieu in the testis in which neoantigens are tolerated yet immune responses to potential 
pathogens are still effective [31]. 
Research suggests that any type of testicular pathology (testicular torsion, genital 
infections), and/or vasectomy, that induces the leakage of antigens beyond what can be 
contained by the aforementioned immunosuppressive mechanisms, would likely produce 
ASA [6]. Indeed, sperm agglutinating and sperm immobilizing antibodies have been 
detected in more than half of vasectomized men [6]. However, unlike in other species, 
male ASA do not induce systemic autoimmune disease [6]. Thus, despite the fact that 
sperm glycans contain epitopes shared by multiple antigens, and therefore would yield 
ASA that react with such common epitopes, among the ASA formed in men, there is a 
greater degree of sperm specific ASA compared to those developed in women [6]. 
Grygielska et al. investigated both the specificities and intensity of ASA produced in 
SCID mice (lacking adaptive immunity) and NOD/SCID mice (lacking both arms of 
immunity) after administering human peripheral blood lymphocytes (PBLs) from either 
ASA-positive or ASA-negative individuals [34]. The NOD/SCID mice allowed for 
unhindered PBLs sensitization and thus the NOD/SCID mice had higher levels of ASA 
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but the NOD/SCID mice also generated ASA that tended to be specifically reactive to 
sperm-membrane antigens. Such specific ASA subsequently showed a greater ability to 
agglutinate sperm. Thus, it may be hypothesized that in males, the breakdown of 
testicular tolerance, or inefficient active immunosuppressive mechanisms, can enhance 
the natural autoantibody response to sperm yielding more mature antibodies that have 
undergone somatic hypermutation and affinity maturation and thereby have a greater 
affinity to sperm antigens. 
Beyond a breakdown in tolerance, there is research suggesting that molecular 
mimicry and cross-reactivity play important roles in the development of ASA. With 
regard to molecular mimicry, it may be that at least some ASA are developed against 
exogenous, pathological antigens and yet these antibodies also bind sperm, because a 
particular sperm antigen may be similar enough in conformation, structure, or amino acid 
sequence, to the exogenous antigen [35]. Kalaydjiev et al. found that the incidence of 
ASA increased in 47% of patients with shigellosis and 42% of patients with 
salmonellosis [36]. All patients in the study had been negative for ASA at the time of 
diagnosis and yet developed clinically relevant titers of ASA within a month after 
diagnosis. A similar finding was evidence by Dimitrova et al. in patients suffering from 
ulcerative colitis and in patients infected with H.pylori [37,38]. Tung et al. found that 
natural sperm autoantibodies cross react with E.coli [39] and Kurpisz and Alexander 
determined that the overwhelming majority of monoclonal antibodies produced against 
sperm cross-react with E.coli and S.typhi [40]. Thus, any disease or infection which can 
disrupt mucosal immune mechanisms and/or directly aid in the leak of bacterial antigens 
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from the bowel, could provoke an immune response in which sperm become an unwitting 
target. 
Other research has emphasized that the inflammatory mediators involved in 
clearing the aforementioned infections, are likely culpable in the development of ASA. 
The unbridled activity of leukocytes, pro-inflammatory cytokines and reactive oxygen 
species (ROS), produced in response to acute, chronic, or latent infections, could 
irrevocably alter or damage sperm. Both exogenous and endogenous ROS production can 
induce an array of negative consequences including the degradation of the sperm 
membrane, sperm DNA fragmentation and chromatin damage, a premature acrosomal 
reaction, and disorders of capacitation [41-43]. Sanocka et al. studied markers of 
oxidative stress in semen samples from fertile and infertile patients with genital tract 
infections (GTI) [44]. In contrast to fertile semen samples with a GTI, infertile samples 
showed continued activation of xanthine oxidase, an enzyme which hampers the ability 
of catalase to remove hydrogen peroxide, long after the offending pathogen was 
eliminated. The ensuing preponderance of pro-oxidant and underwhelming anti-oxidants 
in infertile semen samples, points to the importance of oxidative stress underlying 
infertility. Bozhedomov et al. investigated ROS and its association with ASA [22]. In 
semen samples from infertile men, in which 50% or more of the sperm was coated with 
IgG, the ASA-positive sperm generated significantly elevated amount of ROS when 
compared to fertile, ASA-negative semen samples. Furthermore, the percentage of sperm 
cells with DNA fragmentation in ASA-positive, infertile men was significantly higher 
than infertile men without ASA and in fertile men. However, antioxidant therapy 
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diminished sperm DNA fragmentation, with a simultaneous decrease in ASA. Though the 
exact role of ROS in mediating an autoimmune response to sperm is undoubtably 
complex, it is possible that the accumulation of ROS could lead to the oxidation of lipids, 
proteins, and nucleic acids that overall damage sperm cells. Moreover, ROS-modified 
sperm macromolecules would be more immunogenic than native molecules, because 
epitopes previously hidden could be exposed upon oxidation. Thus, ROS-modified sperm 
antigens would be more readily recognized and internalized by antigen presenting cells 
(APC), which would present them as neo-antigens to lymphocytes. This may also 
promote B cell epitope spreading.  
In B cell epitope spreading, the specificity of an antibody expands from the initial 
epitope that triggered the response, to include either other epitopes of an antigen 
(intramolecular epitope spreading) or another antigen altogether (intermolecular epitope 
spreading). Grygielska et al. immunized SCID and SCID/NOD mice with natively 
glycosylated or deglycosylated sperm antigens [34]. In both mice strains, the 
deglycosylated sperm antigen induced a significantly stronger ASA response, suggesting 
that the deglycosylated sperm antigens were a more powerful immunogen, as sperm 
epitopes were left uncovered. They argue that sperm glycans can be protective- masking 
the more restricted sperm antigens buried under the glycocalyx and preventing an 
immune response to such integral antigens. However, as Paradisi suggests, it is possible 
that these same glycans, which induce a low-affinity immune response (i.e. natural 
autoantibodies) could, in the presence of infection (and downstream oxidative stress), or 
due to a breakdown of immunosuppressive mechanisms, lead to epitope spreading and 
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subsequently can lead to a dangerous specific autoimmune response that hinder sperm 
functioning.  
Essentially, sperm antigens may be more susceptible to becoming antigenic 
targets after being modified by ROS or molecular mimicry may stimulate B-lymphocytes 
to generate cross-reactive antibodies that bind sperm antigens. In any case, once self-
tolerance to a particular sperm antigen is broken, epitope spreading can contribute to the 
development of IgG autoantibodies with exquisite specificity to a sperm-antigen that 
impairs sperm functioning. Bacterial infection could be one element that triggers such a 
cascade of events.  
However, it is still unclear whether the impediment to sperm functioning is due to 
the binding of an antisperm antibody, in and of itself, to an altered sperm antigen, or if 
the impairment to sperm functioning is a consequence of the alteration itself- that a vital 
sperm protein required for fertilization simply no longer functions properly [42]. The 
degree to which ASA impair sperm functioning and fertilization depends on several 
factors; the proportion of ASA-positive sperm, the number and location of those ASA on 
the sperm (head, midpiece/neck, or tail), the affinity of ASA binding, the function of the 
antigen to which the ASA bind and the isotype of the ASA [22].  
 
1.3 ANTISPERM ANTIBODIES AND FEMALE INFERTILITY 
Upon entering the female reproductive tract (FRT) sperm and seminal plasma 
antigens face a relatively hostile environment. Host neutrophils, monocytes, and 
lymphocytes are present in the vaginal, cervical, and uterine epithelium, and could 
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potentially recognize sperm as foreign and mount an immune response [31]. It would 
therefore stand to reason that most women develop ASA upon coitus, however, most 
women, despite regular exposure to sperm and seminal plasma antigens, do not develop 
ASA [6]. Such a finding suggests that the FRT is an immune privilege site. Perhaps more 
so than in any other organ, the immune system’s remarkable ability to adapt to a 
constantly changing environment is paramount. The immune system must concurrently 
manage infection and yet tolerate alloantigens to allow for successful reproduction 
[31,50]. Mechanisms fundamental to striking this delicate balance are numerous. For 
instance, the leukocyte response following the initial deposition of semen into the FRT is 
“silent” in that it occurs in the absence of a significant release of proinflammatory 
cytokines or ROS and serves to eliminate sperm of inferior quality [50]. Indeed, the FRT 
contains unique immune cells, mechanisms of T cell regulation, anti-inflammatory 
cytokine secretions, and reproductive hormones, that all promote alloantigen acceptance 
and protection from sperm isoimmunization [50].  
Components of semen play an important role in this regard. Although sperm lack 
paternal MHC molecules preventing specific MHC-dependent adaptive immune 
responses, innate immune mechanisms must be modulated [50]. Seminal plasma (SP) has 
a host of immunosuppressive factors that nonspecifically dampen the immune response 
within the FRT. In addition, SP induces the expression of cytokines that recruit 
regulatory T cells (Tregs) populations into the FRT. Transforming growth factor (TGF) β 
and PGE2 in SP further augment the recruitment of Tregs, and establish an anti-
inflammatory, Th2 dominate response, within the FRT, that supports alloantigen 
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acceptance [50]. SP components also recruit tolerogenic dendritic cells to endometrial 
tissues [31]. These dendritic cells secrete higher levels of anti-inflammatory cytokines 
and allow for the expansion of specific paternal Tregs that support pregnancy. Finally, 
soluble HLA-G, a molecule known to be found on the surface of extravillious 
cytotrophoblast cells, is found in SP [31,50]. HLA-G, both soluble and membrane bound 
forms, modulates a host of immune responses; inhibiting natural killer cells and CD8+ T 
cells, suppressing IFN-γ, and inducing Treg differentiation [31.50]. Thus, an array of 
diverse immune modulators in SP plays an important role in influencing the response of 
immune cells in the FRT to sperm.   
Similar to the pathogenesis of ASA in males, there are several hypotheses 
regarding the development of ASA in females. Just as GTIs in men have been implicated 
in the pathogenesis of male ASA, the prevalence of ASA in women has correlated with 
gynecological infections. Forty-six percent of women with pelvic inflammatory disease 
(PID) were found to have sera and cervical mucus (CM) positive for ASA, compared 
with a prevalence rate of 20% in women who only had a lower genital tract infection 
[51]. In both men and women, ASA may be generated concurrent with infection with 
chlamydia trachomatis (C.trachomatis). Activated T cells secrete proinflammatory 
cytokines that can activate macrophages into phagocytosing both C.trachomatis and 
sperm [52]. This localized inflammatory process to eliminate C.trachomatis may also 
result in the development of antibodies to sperm [52]. Such an infection could induce an 
immune response that limits the expansion of Tregs specific for male antigens, and 
instead, promotes the release of aberrant cytokines that enhance, rather than modulate, 
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immune response to sperm. This could set the stage for sperm isoimmunization and 
infertility [52,53].  
 Molecular mimicry between sperm antigens and pathogens is also implicated in 
female isoimmunity to sperm. Immunoprecipitation and blotting experiments 
demonstrated shared epitopes between C.trachomatis and human sperm heat shock 
proteins (HSP) [54] and between Ureaplasma urealyticum (U. urealyticum) and human 
nuclear autoantigenic sperm protein (NASP), a protein required for DNA replication [55]. 
Interestingly, ASA incidence in women has been found to correlate with ASA incidence 
in their male partner. Twelve percent of men whose wives were positive for ASA, 
similarly tested positive for ASA. However only 6% of men whose wives were negative 
for ASA tested positive for ASA. Witkin argued that sperm already coated with male 
ASA and subsequently deposited within the FRT, could induce cytokines that would 
activate macrophages and thereby promote the presentation of sperm antigens to T helper 
cells [52,56]. In line with this, Kverka et al. demonstrated that PBMCs from infertile 
women with ASA, infertile women without ASA, and controls, produced markedly 
different cytokines upon encountering sperm cells [57]. Essentially, sensitized 
lymphocytes in the FRT could orchestrate an immune response against sperm, especially 
when sperm are coated with antibody, and this deviant cytokine signaling encourages a 
pro-inflammatory environment in the FRT that compromises sperm functioning.  
Clarke argues that anti-idiotypic antibodies might explain the development of 
ASA in women [49]. The variable domain of an antibody contains the antigen binding 
site (paratope) and thus specifies an antibody’s unique recognition of its antigen. This 
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part of an antibody is referred to as its idiotype or idiotypic determinate, and it is itself 
antigenic, as it can be recognized by anti-idiotypic antibodies. Because the antigen 
binding site or paratope of an antibody mirrors the epitope of a particular antigen, anti-
idiotypic antibodies, which recognize the paratope, have specificities that similarly 
recognize the original antigen [49]. It is possible that if women were continuously 
exposed to semen that contained ASA, they could produce anti-idiotype antibodies 
against the paratope of the ASA, and thereby could initiate an antibody response against a 
sperm antigen because they are complementary to the specificity of the anti-idiotypes 
[49]. Clarke also argues that it is possible that all three mechanisms work in concert to 
induce ASA in women [49]. Either cross-reactive antibodies produced subsequent to 
infection or antibody-coated sperm can cause lymphocytes to secrete pro-inflammatory 
cytokines which can further potentiate and/or maintain an anti-idiotypic immune response 
to ASA in semen. Finally, as Paradisi suggested, natural autoantibodies to sperm may, 
due to a heighted immune response and epitope spreading, become harmful 
autoantibodies specific for sperm antigens that impair sperm functioning.   
 
1.4 CD52G: A TARGET ANTIGEN FOR SPERM AGGLUTINATING ANTIBODIES  
One of several assays to detect ASA is referred to as the complement-dependent 
sperm immobilization test (SIT) [58,59]. This assay involves using a mixture of the 
patient’s sera, sperm, and complement, to detect impaired sperm motility [58,59]. 
Antibodies detected by these assays are referred to as sperm immobilizing antibodies (SI-
Abs) [58,59]. The results of a SIT are represented as a sperm immobilizing value (SIV) 
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[58,59]. If the SIV is positive, then a quantitative SIT is performed, in which a patient’s 
serum is serially diluted to determine the dilution that retains sperm motility up to 50% 
[58]. Assessment of this titer in infertile women is an important diagnostic tool and helps 
to determine which treatment method is most appropriate for a particular patient, 
depending on the degree to which SI-Abs may underly their infertility [58,59]. SI-Abs are 
most frequently found in the sera of women with unexplained infertility, with an 
incidence of 10%-15% [58]. Moreover, women with SI-Abs in their sera were found to 
have these antibodies at comparable levels in their cervical mucus (CM) and peritoneal 
and follicular fluids [60].  
ASA can have both immobilizing and agglutinating activities. The term, 
agglutination, describes an ASA mediated phenomena, in which sperm stick to each 
other, usually in particular patterns, like head-to-tail. Assays measuring the extent to 
which ASA agglutinate sperm include the Sperm Escape Assay and the Agglutination 
Kinetic Assay. These tests infer the agglutinating ability of ASA by measuring either, the 
number of free, motile sperm that escape agglutination, or by measuring the time it takes 
to agglutinate a given concentration of sperm cells, upon exposure to ASA. Computer 
assisted semen analysis (CASA) software, that analyzes and assess sperm motility, as 
well as, manual microscopic methods are used to conduct these assays. 
Elucidation of the epitopes recognized by SI-Abs is necessary for determining the 
mechanism by which these antibodies impair sperm motility. Such knowledge could 
provide a basis for the development of a treatment specific to ASA-mediated infertility 
[61]. To achieve this goal, given the heterogenous nature of ASA, Koyama et al. 
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established a human-mouse hybridoma that secreted high titers of a human monoclonal 
SI-Ab and designated it H6-3C4 [62]. The monoclonal antibody (mAb) H6-3C4 was of 
the IgM isotype and readily immobilized and agglutinated sperm. Immunofluorescent 
stainings of the male reproductive tract (MRT) with H6-3C4 revealed that the antibody 
reacted exclusively with the cauda epididymis but not the testis or other somatic tissues 
[63,64]. Western blotting and SDS-PAGE analysis of the immune complexes formed 
between H6-3C4 and sperm extracts, showed that the amino acid sequences of the 
proteins precipitated by H6-3C4 were found to be identical to those of human 
glycoprotein CD52 [63,64].  
 Human CD52 is expressed on the surface of a host of immune cells, including 
mature lymphocytes, monocytes/macrophages, and dendritic cells, among others. It was 
originally detected as an antigen recognized by the rat mAb Campath-1 [65]. Humanized 
Campath was first used in 1982 for the treatment of non-Hodgkin lymphoma [66]. 
Decades later, under its new name, Alemtuzumab, it has been used for the treatment of 
multiple sclerosis (MS), chronic lymphocytic leukemia (CLL) and in kidney 
transplantations for anti-rejection therapy [66]. The physiological role of CD52 in 
modulating immune activity remains to be fully explicated. 
However, it is known that Campath is capable of inducing complement-dependent 
cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and 
caspase-dependent apoptosis in leukocytes [66-68]. CD52 is also believed to play a 
significant role in regulating the activities of T cells, capable of acting as both an 
activator and inhibitor of effector and regulatory T cells [68]. Campath was also found to 
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be reactive with human sperm, capable of immobilizing and agglutinating sperm, similar 
to that of H6-3C4 [64]. This was due to the fact that CD52 expressed in leukocytes and in 
MRT tissues share a common core protein. The core protein is composed of only 12 
amino acids tethered to the plasma membrane via a glycosylphosphatidylinositol (GPI) 
anchor [6,68]. However, distinct structural modifications exclusive to mrt-CD52 (CD52g 
present on the surface of sperm, the epididymal epithelium, and in male reproductive 
tract fluids) but not expressed on leukocyte-specific CD52 were soon noted.  
One such difference is that mrt-CD52 (CD52g) is more heavily glycosylated, 
having both O-linked and N-linked carbohydrate moieties that are almost completely 
sialylated and fucosylated [69]. Disparate glycosylation patterns explained the curious 
finding that H6-3C4 only reacted with sperm and not with lymphocytes. Western blot 
analysis of sperm extracts revealed that CD52g contained a unique glyosidic bond within 
its N-linked carbohydrate chain that H6-3C4 recognized [6,70]. Meanwhile, Campath 
was found to bind to the last three amino acids of CD52’s core protein and components of 
the GPI anchor [69]. The structural differences between mrt-CD52 (CD52g) and 
leukocyte-CD52 implied that there are different physiological functions between the two 
proteins. The unraveling of the biology of both proteins is under investigation. However, 
research has provided the means for much conjecture regarding the function of CD52g. 
 As sperm embark on their developmental journey through the epididymis, the 
epididymal epithelium, via apocrine section, releases extracellular microvesicles called 
epididymosomes, into the intraluminal compartment of the epididymis [71]. CD9-
positive epididymosomes preferentially fuse with sperm and are thought to transfer 
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CD52g into the maturing sperm membrane via its GPI anchor [30,71]. Thus, CD52g is 
found in abundance in epididymal sperm and in the ejaculate. Since sperm motility is one 
of the chief characteristics acquired by epididymal sperm, it is possible that CD52g’s 
concomitant appearance functions to ensure sperm acquire this pivotal function [30,72]. 
CD52g’s sialylated N-linked glycans, as well as, the nature of its O-linked glycans, 
confers a negative charge to CD52g that is thought to contribute to the net negative 
charge of the sperm surface [6]. This negative charge may prevent sperm from 
agglutinating with itself [6,15]. Flori et al. found that CD52g binds semenogelin I, one of 
the predominant structural proteins that constitutes a loose gel formed by semen after 
ejaculation [73]. Some of these CD52 molecules with bound semenogelin I are cleaved of 
their GPI anchor as this gel is degraded, thereby releasing sperm to penetrate cervical 
mucus [73]. Thus, CD52g is thought to play a central role in both the coagulation and 
liquefaction of semen [73].  
 Given that H6-3C4 and Campath were known to induce a complement-dependent 
cytotoxicity, Koyama et al. wanted to demonstrate the manner in which CD52g 
modulated the complement cascade. Koyama et al. used a hemolytic assay based on the 
Mayer method, in which sensitized sheep erythrocytes are exposed to titered complement 
components in sera [74]. Upon addition of CD52g, the titer at which 50% hemolysis 
occurred was significantly reduced [75]. In fact, the degree of hemolysis was reduced by 
CD52g in a dose dependent manner. However, the addition of antibody against CD52g 
reversed this trend, spurring the lysis of erythrocytes [75]. Thus, CD52g seemed to inhibit 
complement mediated cytotoxicity. Subsequent investigations determined that purified 
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CD52g reduced complement activity via the classical pathway [75]. Hardiyanto et al. 
conducted immunoprecipitation assays to determine at what stage of classical 
complement pathway CD52g functioned [76]. CD52g in epididymosomes and 
membrane-bound CD52g were both found to bind to complement component 1q (C1q), 
the initial protein that induces the classical pathway [76]. CD52g bound to C1q via its N-
linked carbohydrate chain, a MRT-specific sperm modification [76]. Thus, this unique 
carbohydrate modification of CD52g may protect sperm in the FRT by inhibiting the 
function of C1q. If any immune complexes form on the surface of the sperm membrane, 
CD52g may regulate classical complement activation, such that bound ASA fail to exert 
any toxic effect [76]. However, if an antibody is raised against CD52g, it could negate its 
ability to protect sperm from complement-mediated lysis, when sperm enter the FRT 
[76]. Intriguingly, CD52 has been found in the female reproductive tract, perhaps 
indicative of a role protecting the developing oocyte as well as the embryo from 
complement activation [77].  
 
1.5 MECHANISMS OF ANTISPERM ANTIBODY MEDIATED INFERTILITY  
Another means by which ASA are thought to interfere with fertility is by 
compromising the ability of sperm to penetrate cervical mucus [78]. Under the influence 
of estrogen, the cervix secretes an extremely watery mucus (CM). CM represents an 
important barrier, through which sperm must pass, if they are to survive the stringent 
selection process they are subjected to as they traverse the FRT [79]. ASA impair the 
ability of sperm to penetrate this CM. The movement of sperm through CM is likely 
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influenced by an interaction between sperm and CM components (mucin glycoproteins 
and lipids). ASA coating the sperm surface could bind mucins and effectively trap sperm 
in CM [51]. The isotypes of ASA responsible for this impaired migration are 
predominantly IgA antibodies directed against the sperm head and IgG ASA directed 
against the neck or midpiece of sperm [51]. The inability of sperm to breech the CM is 
also a consequence of complement activation via either IgA or IgG ASA [51]. D’Cruz et 
al. used flow cytometry to demonstrate that exposing sperm to IgG ASA resulted in the 
deposition of complement components (C3d and C5b-C9) on the sperm surface [80]. This 
immobilizes sperm and induces the activation of granulocytes to the antibody and 
complement bound sperm [80]. Although researchers have not yet reached a consensuses 
on whether complement components are sufficiently present throughout the FRT to 
induce the aforementioned effects [51], it has been documented that complement 
components in CM were able to immobilize 50% of ASA-coated sperm after 1 hour and 
70% after 3 hours [81]. ASA have also been found to hinder sperm migration from the 
uterus into the fallopian tubes [60].   
The effects of ASA on capacitation, the acrosome reaction, and the ability of 
sperm to bind to the oocyte are thought to be determined by the antigenic specificity of 
ASA [51]. Sperm membrane proteins are dynamic- they form unique complexes, in 
specific locations, at specific times in the lifetime of an individual sperm and each 
complex has a specialized role in fertilization [82]. Thus, the characterization of 
immunogenic sperm proteins necessary for processes like capacitation, need to be 
elucidated, so that the role of cognate ASA can be determined. Given this, an interesting 
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study investigated the incidence of ASA-interference with zona pellucida (ZP) binding 
[83]. Fifty percent of patients whose ejaculated sperm was coated at the sperm head with 
IgG or IgA had impaired ZP binding [83]. However, the ASA coated sperm were able to 
bind to the ZP to some degree; zona pellucida binding was never entirely prevented by 
ASA [83]. The researchers concluded that when it comes to the role of ASA in impairing 
gamete interaction, what matters most is the relevance of the specific antigen [83]. 
Francavilla and Barbonetti argue that the degree to which ASA exerts a negative effect on 
fertilization, downstream of cervical mucus penetration, is hard to establish because it 
requires an assay that can quantify the amount of ASA on the sperm surface and 
knowledge of both the antigen of each ASA, and the role each antigen plays in mediating 
a successful sperm/oocyte interaction [84]. Research into these complexities is warranted, 
not only because it would further basic knowledge in reproductive biology but also 
because it would help physicians to choose the most effective and least invasive assisted 
reproductive treatment option for those with ASA-mediated infertility [84].   
Much of the research into the etiology of ASA formation and the effects of ASA 
on the mechanisms underlying fertilization, was conducted over 20 years ago and needs 
to be repeated. The complex nature of ASA is testament to the complexity of the immune 
response in human genital tracts. Due to this complexity, questions regarding the very 
nature of ASA remained unanswered. The presence of ASA in prepubescents, and in both 
fertile and infertile adults, yet their rarity in the population as a whole, makes delineating 
whether they are an uncommon, or all-too-common, immunologic phenomena a 
challenge. The fact that the majority of ASA are not inherently sperm specific, but react 
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with pathogenic and endogenous epitopes, begs further investigation. Understanding the 
functional relevance of oligosaccharides that coat the sperm surface could elucidate why 
SI-Abs preferentially target carbohydrate moieties. Although hypothesis that seek to 
resolve these discrepancies were discussed, conclusive answers will only be brought 
about through continued research. ART are a backroad currently used to circumvent the 
molecular processes mediating fertilization that remain an enigma. Therefore, continued 
research into ASA, such as anti-CD52g, is of cardinal importance, for it has advanced our 
understanding of the immune mechanisms underlying fertilization, has contributed to the 
development of novel contraceptive methods, and has the potential to improve the 














CHAPTER 2. LITERATURE REVIEW OF ENZYME-LINKED IMMUNOSORBENT 
ASSAYS (ELISA) 
2.1 THE HISTORY OF ENZYME-LINKED IMMUNOSORBENT ASSAYS 
The ELISA was pioneered by Peter Perlmann and Eva Engvall at Stockholm 
University in Sweden in 1971 [85]. Perlmann and Engvall combined aspects of 
immunofluorescent assays (IF) developed in the 1940s [86] and radioimmunoassay (RIA) 
introduced in the late 1950s [87]. RIA was a rather laborious process in which a specified 
concentration of the antigen of interest was radio-labeled and bound to an antibody, 
which was itself attached to a solid material [87]. The concentration of the antigen of 
interest in test sera was determined by the extent to which the sera derived antigen 
displaced the radio-labeled antigen [87]. In a desire to circumvent the use of radioactive 
labels, Avrameas et al. optimized the use of enzyme conjugated antibodies to detect the 
presence of immune complexes in the late 1960s [88]. Utilizing these techniques, 
Perlmann and Engvall developed a direct ELISA, in which an enzyme, alkaline 
phosphatase, rather than radioactive iodine, was used as an antibody label, to successfully 
quantify the level of IgG in rabbit serum [85,89]. The ELISA method provided to be 
easier, cheaper, and more adaptable than RIA or IF, and yet still retained the specificity 
and sensitivity required of a diagnostic tool [90]. The great versatility of the ELISA 
method is due to the fact that a researcher can vary the combinations of reagents used, 
depending on the objective of the assay [91]. The technique is simple, utilizing materials 
and equipment that are relatively inexpensive and require no extensive training or 
certification [91]. Furthermore, owing to enzyme amplification, ELISAs are sensitive 
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[92] and yield quantifiable data [91]. The ELISA would be modified over the next forty 
years to allow for the detection of a plethora of proteins found in human sera. Throughout 
the 1970s ELISAs were used to quantify the amount of antibodies in sera to strains of 
Salmonella [93], to detect cholera exotoxin [94] and infections caused by influenza and 
mumps [85]. Today, ELISAs are ubiquitous in diagnostic laboratories around the world 
[85]. They are employed for the detection of hepatitis A [95] and B [96], rheumatoid 
factor [97,98], HIV [99,100] and antinuclear antibodies [101]. ELISAs have still wider 
applications in various industries (food and pharmaceutical) as well as in both basic and 
applied scientific research [89]. The ELISA is thus a remarkable technique in that it’s a 
straightforward assay, composed of simple, well-understood constituents, that has aided 
in the understanding of a diverse array of complex, unexplained biological phenomena.  
2.2 ELISA: OVERVIEW OF THE PRINCIPLE AND PROCEDURE  
ELISAs are conducted to detect and measure the concentration of biomolecules 
[89,91]. The general mechanism by which this is accomplished involves at least one 
antibody and its cognate antigen. The antigen of interest is immobilized, either by passive 
absorption to a 96-well plate, or by binding to an antibody, referred to as the capture 
antibody, that is itself absorbed to the plate [89,91]. The antigen or capture antibody will 
not bind to every conceivable site on the plastic well. Therefore, to prevent nonspecific 
absorption of proteins to these empty sites, a blocking agent is employed [89,91]. An 
enzyme-labeled antibody is subsequently added and binds to any immobilized antigen 
[89,91]. Upon addition of the proper substrate, the enzyme will catalyze a reaction that 
produces a colored product [89,91]. The intensity of the color generated from this 
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enzymatic reaction constitutes a signal that can be measured via colorimetry and 
correlates with the amount of antigen on the plate [89,91]. Substrate catalysis can be 
stopped via the addition of a strong acid that quickly denatures the enzyme [89,91]. 
Between the addition of each reagent in an ELISA, the plate is incubated and washed 
[89,91].   
 
2.3 TYPES OF ELISAs 
Depending on the objective of the assay, different strategies for conducting an 
ELISA have been established. They differ in how the antigen is immobilized and 
detected. There are three basic approaches to conducting an ELISA, each of which can be 
modified in the event that a competitive assay is required [91]. A direct ELISA involves 
adding the antigen of interest to the surface of the plate. Enzyme-labeled antibodies are 
subsequently added and bind directly to the immobilized antigen (Figure 1a). An indirect 
ELISA largely follows the same steps as a direct ELISA, except for the stage at which the 
enzyme-linked antibodies are added. After the antigen has been immobilized to the plate, 
cognate primary or detector antibodies are added. However primary antibodies are not 
enzyme-conjugated. The primary antibodies are themselves targeted by enzyme-
conjugated antibodies (Figure 1b). Thus, the conjugated antibodies bind indirectly to the 
antigen, via binding to the primary antibody. The enzyme-linked antibodies are referred 
to as anti-species conjugates, as they are specific to the antibodies of the species in which 
the primary antibodies are generated [91]. For instance, if the primary antibodies were 
produced in rats, the enzyme-conjugated secondary antibody must be an anti-rat 
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antibody. Direct ELISA are constrained by the fact that the primary antibody must be 
enzyme conjugated [91]. Indirect ELISAs compensate for this, as there are thousands of 
commercially available secondary anti-species conjugates, of various isotypes, that can 
be used to detect particular primary antibodies in the assay [91]. Thus, indirect ELISAs 
are more flexible than direct ELISAs and are consequently more commonly used. 
Essentially, a single secondary antibody with the particular isotype of interest can be used 
to report the presence of many antibodies against a particular antigen. The sensitivity of 
the assay is also enhanced, as many secondary antibodies can bind to epitopes on the 
primary antibody, increasing the signal generated upon catalysis [91]. Yet one pitfall of 
indirect ELISAs is that they have varying degrees of non-specific binding [89,91]. 
Different species produce antibodies that share evolutionary conserved sequences. 
Therefore, it is possible that the paratope of an antibody generated in one species, could 
recognizing an epitope on an antibody from a different species [89,91]. This could result 
in a secondary antibody unintendedly binding to off-target, endogenous antibodies in the 
test sample and a falsely elevated signal would result.  
To ensure greater specificity, a sandwich ELISA can be employed (Figure 1c). In 
this method, the antigen of interest is sandwiched between two antibodies. The first 
antibody, the capture antibody, is immobilized to the surface of the plate and selectively 
captures the antigen of interest. The second antibody bound to the captured antigen can 
be either enzyme conjugated (direct sandwich ELISA) or a detector antibody that is 
subsequently targeted by a labeled antibody (indirect sandwich ELISA). Sandwich 
ELISAs allow for a variety of different test samples to be tested against a single capture 
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antibody with a particular specificity, or for a variety of capture antibodies to be tested 
against various samples, on the condition that the enzyme-conjugated antibody does not 




2.4 STAGES IN ELISA 
Each component required to conduct an ELISA has unique characteristics that 
account for the phenomena and influences the degree to which accurate, reliable, and 
reproduceable results are obtained. The first step in an ELISA involves coating a 96-well 
plate with either antigen or capture antibody. The 96-well plates typical of an ELISA are 
manufacture from polystyrene (PS), a hydrophilic polymer. Nonpolar protein components 
are thought to absorb to the PS plate via hydrophobic interactions [91]. In a sandwich 
ELISA, it is imperative to discern the appropriate concentration of capture antibody that 
must be added to the plate, as the manner in which capture antibodies absorb to the plate 
Figure 1. Types of ELISAs. a) Direct,  b) indirect, and c) indirect 
sandwich ELISAs, are three approaches to detecting and quantify the 
concentration of an analyte using immune complexes. 
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can affect the results of the assay. If the concentration is too high, steric hindrance may 
prevent the antibodies from absorbing to the plate or may cause antibodies to stack on top 
of one another [91]. In both cases, the likelihood of a stable interaction between the 
capture antibodies and the antigen of interest decreases. Moreover, the orientation of the 
capture antibodies, and the degree to which the majority of the antibodies bind to the 
plate via their Fab portion, rather than their Fc portion, influences the amount of antigen 
captured [91]. Ideally, capture antibodies would absorb to the plate via their Fc and 
would be evenly spaced along the surface of the well, to allow for the maximum 
concentration of antigen to bind [91]. Another significant factor influencing the degree to 
which the capture antibodies or antigen absorb to the plate, is the length of time both are 
incubated and the temperature at which that incubation occurs. Higher temperatures 
increase the rate of protein absorption, but could potentially damage the protein 
components used to coat the plate [91]. The concentration of antigen or antibody used to 
coat the plate, also influences the incubation time required to ensure that a maximal 
number of hydrophilic interactions between the coating mixture and the plastic matrix 
occur [91].  
After the first biomolecule has been immobilized on the plate, it is necessary to 
ensure that any extraneous proteins in the test sample, or any antibodies introduced in 
subsequent steps of the ELISA, do not absorb to the plate. If such proteins were to 
occupy empty spaces on a well, the anti-species conjugate could bind to these and give a 
falsely elevated signal [91]. To prevent such binding, one method involves incubation of 
a blocking agent to the plate before addition of the test sample. Common protein blockers 
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include bovine serum albumin (BSA) and non-fat dry milk [91]. These proteins attach 
permanently to any empty spaces on the surface of a well, preventing irrelevant proteins 
from doing so [91]. Another method to further prevent nonspecific binding is to add a 
low concentration of detergent to the dilution buffer of reagents used in the assay [91]. 
These detergents prevent and disrupt weak, nonspecific protein-protein interactions 
which could similarly give rise to a misleading, elevated signal.  
 Fundamental to ELISAs is the use of enzyme-conjugated antibodies to report the 
presence of a particular antigen. There are various enzymes that are readily amenable to 
conjugation with an antibody [91]. However, the most studied enzyme-antibody 
conjugate and one of the most commonly used, is horseradish peroxidase (HRP) [91]. 
Discovered in 1903, HRP is a heme containing protein extracted from the roots of the 
horseradish plant (Armoracia rusticana) [102]. Peroxidases are a large collection of 
enzymes that catalyze the oxidation of peroxides [102]. The reaction mechanism of HRP 
mediated catalysis is complex [102] but, essentially, HRP breaks down two molecules of 
hydrogen peroxide into water and oxygen. This is achieved by the reduction of hydrogen 
peroxide, as the heme group of HRP is simultaneously oxidized, to yield an unstable HRP 
intermediate. This intermediate has a lower affinity for the second molecule of hydrogen 
peroxide and one can select a hydrogen donor, such as 3,3′,5,5′ tetramethylbenzidine 
(TMB), to be oxidized by the HRP intermediate and thereby regenerate the native HRP. 
This redox reaction is exploited in ELISAs. When a hydrogen donor like TMB is 
oxidized, it yields a blue reaction product [91]. The colored product serves as a measure 
of the activity of the HRP enzyme and thus, in an ELISA, should indicate the presence of 
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immune complexes and by extension, allows for the detection and quantification of 
antigen of interest.  
To stop the redox reaction, a strong acid such as sulfuric acid, is often utilized to 
denature HRP [91]. Stopping the reaction expedites the measurement of the colored 
product, as a single endpoint measurement can be obtained, rather than monitoring the 
rate of the reaction over time [91]. Therefore, once the stopping reagent has been added, 
the reaction product is measured by a colorimetric assay [91]. A beam of light is directed 
through each well of the plate. A plate reader derives the amount of light absorbed in 
each well based on the transmittance. Each well is given an absorbance value in optical 
density. The intensity of the color of the solution in each well represents the amount of 
protein of interest present in the test sample. Adding the stopping reagent before reading 
the plate alters the color of the test solution from blue to yellow, with a maximum 
absorbance at 450nm [91]. Thus, in an ELISA, the plate reader transmits light (at 450nm) 
through each well and determines how much light of that wavelength is absorbed by each 
test sample. 
After the addition of each reagent in an ELISA, the plate must be incubated and 
subsequently washed.  The incubation period provides time for specific antigen-antibody 
interactions to occur [91]. As the antigen and antibody must to come into close enough 
contact to allow for their characteristic non-covalent bonds to be established, the 
incubation period is essential. However, numerous factors affect this interaction including 
the concentration of the antibodies and antigen, and the time and temperature of the 
incubation [91]. The washing process involves emptying the plate wells and flooding 
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them with washing buffer three times. Flooding the wells with the wash buffer is 
undertaken to remove any unbound (irrelevant) reagents from the wells and thereby 
increase the accuracy of the ELISA, as only those reagents that react with the antigen or 
antibodies introduced in the different phases of the ELISA remain in the well [91]. A 
common washing buffer is phosphate-buffered saline (PBS) mixed with a small 
concentration of the detergent Tween-20 [91]. The detergent serves to further break up 
any nonspecific protein-protein interactions such that extraneous proteins can be removed 
from the assay [91]. If such extraneous proteins (such as endogenous sera antibodies) 
were to remain in the well, they could be detected in the following phases of the test, 
giving a high background signal. Knowledge of the systems, stages, and components of 
an ELISA will all be considered in order to optimize the performance of the assay to 
detect CD52g antibodies in human sera. 
2.5 ELISA: A TOOL FOR THE QUANTIFICAITON OF CD52G ANTIBODIES IN 
HUMAN SERA 
 An overview of the initial indirect and the sandwich ELISA protocols used to 
detect CD52g antibodies will be described below, accompanied by a pictorial 
presentation (Figure 2) of these steps. The experimentally derived specifics of each step, 
as well as modifications to these protocols, will be described in Chapter 3. 
 When developing an ELISA for CD52g Abs in serum, two ELISA techniques 
were utilized, a typical indirect and sandwich ELISA. In the indirect ELISA, CD52g is 
bound inside the wells of the plate via coating the wells with seminal plasma (SP). 
Human sera from patients with infertility are subsequently introduced. If CD52g 
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antibodies are present in the sera, binding to CD52g will occur. The addition of anti-
human IgG that has been enzyme (HRP) linked indicates the degree to which anti-CD52g 
antibodies are present in each serum sample. In addition, controls, as well as, solutions 
containing known concentrations of CD52g antibodies are tested. A standard curve is 
constructed using optical density values. The standard curve is used to calculate the 
relative concentration of CD52g antibodies in each patients’ sera. In a sandwich ELISA, 
rather than coating the wells with CD52g/SP, the wells are coated with Campath and 
CD52g/SP is added in a subsequent step. Between each step in either type of ELISA, 
there is an incubation period, followed by washing with 0.05% Tween-20 in PBS. What 
follows is an outline of the indirect and sandwich ELISA protocols for detecting and 



































Figure 2. Schematic of Indirect and Sandwich CD52g ELISA 
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Step 1. Coating:  The first step in both an indirect and sandwich ELISA requires a 96 
well plate. In an indirect ELISA, seminal plasma, containing CD52g, is diluted in an 
appropriate buffer and coats the bottom of each well. In a sandwich ELISA, the plate is 
coated with diluted Campath, a monoclonal antibody against the protein core of CD52g. 
Campath is used as the capture antibody in this assay. Campath concentrations are 
calculated in µg/ml, indicating the amount of the antibodies that are present in solution. 
 
Step 2. Blocking: The major component of fetal bovine serum (FBS) is bovine serum 
albumin (BSA). In the blocking step, diluted FBS is added to the plate, such that BSA 
can absorb to regions of the well surface that are not covered by the antigen or by the 
capture antibody. BSA will thereby prevent non-specific antibody binding to the plate. 
 
Step 3. Addition of sera test samples, antibody standards, and controls: Test samples 
of human sera are diluted into a buffer. Solutions with known amounts of the CD52g 
antibody HCA-4, are diluted in a range of concentration for use as a set of antibody 
standards. HCA-4 (Human Contraceptive Antigen-4) a humanized monoclonal antibody 
raised against the carbohydrate moiety of CD52g. Each serum sample is added to 
individual wells on the plate in duplicate or triplicate. The HCA-4 standard 
concentrations are calculated in µg/ml. Positive and negative controls were added as a 




Step 4. Addition of Conjugated Antibody:  The conjugated antibody added is an anti-
human Immunoglobulin G (IgG). The IgG has been conjugated with HRP.  If the serum 
sample added to the plate is positive for CD52g antibodies, the conjugated IgG antibodies 
will bind to any CD52g antibodies that have bound to CD52g inside the well. If, 
however, there are no CD52g antibodies in the test sample, the conjugated antibody will 
be removed during the washing step. Thus, theoretically, only the wells containing sera 
that are positive for CD52g antibodies will contain the conjugated antibody. 
 
Step 5. Addition of HRP substrate: The substrate that is added is 3,3’,5,5’-
tetramethylbenzidine (TMB). The oxidation of TMB causes the solution in each well to 
become a blue color. The intensity of this color is indicative of the amount of CD52g 
antibodies. The reaction is then quenched using sulfuric acid. 
 
Step 6. Reading: The ELISA plate is inserted into a plate reader which reads each well 
by colorimetry at 450nm. The intensity of the color in each well is given in optical 
density, which is directly proportional to the amount of CD52g/CD52g antibody binding 
that occurred within the well. The optical density values for each of the antibody 
standards is used to plot a standard curve.  
Note: In a sandwich ELISA, the protocol is slightly different in that diluted SP, 





2.6 OBJECTIVES OF THE CURRENT STUDY 
The chief objective of this study was to develop and optimize an ELISA to determine the 
prevalence of CD52g antibodies in the sera of patients with infertility as compared to 
controls. The second objective was to determine if there was a correlation between 
patient sera that was shown to agglutinate sperm and the prevalence of CD52g antibodies 
in these samples.  
 
CHAPTER 3. DEVELOPMENT OF AN ELISA FOR THE DETECTION OF CD52G 
ANTIBODIES IN HUMAN SERA 
The initial methods used to produce an ELISA to measure the concentration of CD52g 
antibodies will be described first. A description of the modifications made to this 
procedure as a consequence of experimentation conducted for this study will 
subsequently be detailed.  
 
3.1 MATERIALS AND METHODS  
Sandwich ELISA: Method for Coating ELISA Plates with Capture Antibody 
Campath (1000 µg/mL), a commercially available monoclonal antibody (IgG2b) against 
the protein core of CD52g is diluted in PBS. This solution constitutes the coating buffer. 
The coating buffer (50µL/well) is added the ELISA plate. The plate is sealed with an 
adhesive, clear, plastic cover to prevent the reagents from evaporating or being 
contaminated. The plate is subsequently incubated overnight at 37℃. Following 
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incubation, the plate cover is removed and the coating buffer is discarded. The plate is 
washed three times with PBS (200µL/well).  
 
Method for Blocking ELISA Plates 
The blocking buffer consists of PBS with 5% Fetal Bovine Serum (FBS). The blocking 
buffer (200µL/well) is added to the ELISA plate. The plate is sealed and is incubated at 
37℃ for 1 hour. Following incubation, the blocking buffer is discarded and the plate is 
washed three times.  
 
Method for Seminal Plasma (SP) Addition 
Indirect ELISA: SP Coating   
Frozen aliquots of seminal plasma (SP) are brought to room temperature. The SP is 
diluted in PBS. The SP solution (200µL/well) is added to each individual well of the 
plate, such that it absorbs to the well surface. The plate is sealed and is incubated 
overnight at 37℃.  
Sandwich ELISA 
Frozen aliquots of SP are brought to room temperature. SP is diluted in sample diluent. 
The sample diluent is composed of PBS with 10% FBS and 0.5% Triton X-100. The SP 
solution (200µL/well) is added to each well of the ELISA plate, such that molecules of 
CD52g contained within it can be captured by Campath antibodies coating the plate. The 
plate is sealed and is incubated at 37℃ for 2 hours. Following incubation, the SP is 
discarded and the plate is washed three times with wash buffer.  
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Method for Preparation of Serum Samples, Controls, Antibody Standards and Conjugate 
Antibody  
As the SP is incubating, the antibody standards are produced. The humanized monoclonal 
antibody (IgG1) HCA, raised against the carbohydrate epitope of CD52g is used to 
prepare standard solutions. Concentrated HCA is serially diluted in sample diluent to 
known concentrations and added to the plate (50µL/well). Aliquots of each serum sample 
are brought to room temperature, vortexed, and subsequently diluted in sample diluent 
and vortexed again before addition to the plate (50µL/well). Horseradish peroxidase 
(HRP) conjugated anti-human rabbit Immunoglobin G (IgG) is added to PBS to create a 
1:5000 dilution and added to the plate (100µL/well).  
Method for Conducting an ELISA Assay 
After the plate was blocked and CD52g has been immobilized to the plate, the HCA 
standards and the serum samples were added in duplicate or triplicate to the microtiter 
plate. The loaded assay plate was sealed and incubated at 37℃ for 1 hour. The plate was 
washed with wash buffer three times to remove any unbound material from the well. The 
conjugated antibody was added to each well and the plate incubated for 1 hour at 37℃. 
The plate was subsequently washed three times with wash buffer to remove any unbound 
conjugate antibody. The HRP substrate, 3,3’,5,5’-tetramethylbenzidine (TMB, 
100μl/well), was added to each well. The liquid in the wells that contained CD52g 
antibodies should turn a blue color. The plate was incubated at room temperature to allow 
time for the blue color to develop. Theoretically, the intensity of this color should 
correlate to the concentration of anti-CD52g antibodies in the original serum sample. 
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Sulfuric acid (2M, 100µL/well) was added to each well to quench the HRP-catalyzed 
reaction. Sulfuric acid was added when the lowest standard turned blue, approximately 
15-20 minutes after the addition of TMB. Upon addition of sulfuric acid, the liquid in the 
plate turn a yellow color. The plate is then inserted into a plate reader which assigned an 
optical density value to each well via absorbance colorimeter at 450nm. The standard 
curve is generated from the known concentrations of the HCA standards. The 
concentration of anti-CD52g antibodies can be derived from this curve. 
 
Method for Washing Plates 
After the addition of each reagent, the ELISA plate is washed three times with wash 
buffer. The wash buffer is composed of PBS with 0.05% Tween-20 (200µL/well). After 
flooding the plate with wash buffer, the plate is inverted and the buffer is discard into the 
sink. The inverted plate is tapped against paper towels to remove any residual buffer.   
 
Statistical Analysis of ELISA Data  
A Repeated Measures ANOVA (analysis of variance) procedure was used to compare the 
mean absorbance values derived from antigen coated and non-antigen coated 
(background) wells for all serum samples. If the results of the ANOVA were significant 
(p< 0.05), post-hoc analysis was conducted via the Tukey Test. GraphPad Prism, a 
commercial graphing and statistics software was used to perform these analyses and 







3.2 SANDWICH ELISA: OPTIMIZATION OF CAPTURE ANTIBODY AND 
PRIMARY ANTIBODY CONCENTRATIONS  
 
Optimization of Campath Concentration  
The considerable specificity of sandwich ELISAs engendered them as the best strategy 
for detecting CD52g antibodies in the complex milieu of human serum. Campath is a rat 
monoclonal antibody specific to the protein core of CD52g. When used as a capture 
antibody, Campath immobilizes CD52g from seminal plasma via an antigen/antibody 
interaction. The first stage of this study involved determining the proper concentration of 
Campath that would constitute the coating buffer. A microtiter plate was coated with two 
different concentrations of Campath (10µg/mL or 20µg/mL) to test its affect on assay 
performance.  
 
Optimization of Primary Antibody (HCA) Concentration 
The humanized monoclonal antibody HCA-4 (470µg/mL) was used the primary 
antibody. HCA is raised against the carbohydrate moiety unique to CD52g. As Campath 
would immobilize CD52g via binding to CD52g’s protein core, HCA would bind to 
CD52g specific glycans. HCA would serve as a positive control and/or standard in 
subsequent experiments to detect CD52g antibodies in human sera. Therefore, it was 
necessary to determine the appropriate concentration of HCA-4 to detect CD52g 
immobilized by Campath (at 10µg/mL or 20µg/mL). This was accomplished by serially 
diluting HCA-4 and examining the resulting trend in the signal generated.   
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Production of Assay Components 
A typical capture antibody concentration of 10µg/mL was tested against a concentration 
of 20µg/mL. An amount of concentrated Campath was added to PBS to produce the two 
desired concentrations. Each coating buffer, with a concentration of Campath at either 
10µg/mL or 20µg/mL, coated 18 wells on one plate. Seminal Plasma (SP) was brought to 
room temperature. A 1:10 dilution of SP (200µL/well) was used for this assay. A 2-fold 
dilution series of HCA-4 starting at a concentration of 100µg/mL was assayed. Since 
100µg/mL of HCA was previously determined to be the optimal concentration at which 
HCA agglutinated sperm, this was the highest HCA concentration to be tested for its 
ability to detect CD52g in ELISA. The recommended dilution factor for the conjugate 
antibody, rabbit anti-human IgG, ranged between 1:1000-1:10,000. Therefore a dilution 
factor of 1:5,000 was selected.  
Assay 
Two concentrations of Campath and six different concentrations of HCA-4 were assayed 






























The first experiment conducted sought to determine the optimal concentrations of both 
the capture antibody, Campath, and the primary “detector” antibody HCA-4. As shown in 
Figure 3, the strongest signal was obtained with Campath at 10µg/mL and HCA-4 at 
100µg/mL. The higher concentration of Campath (20µg/mL) may have exceed the 
binding capacity of the surface of the plate, such that the ability of Campath antibodies to 
distribute evenly on the well surface, via their Fc, was impaired. This would have 
resulted in Campath antibodies either failing to trap CD52g or, conversely, capturing 
CD52g, but due to failed absorption, being removed upon washing. In either case, the 
depressed signal at the higher concentrations of Campath (Figure 3) would result. The 
concentration of HCA-4 at 50 µg/mL or higher, exceeds the concentration of CD52g 
Figure 3. Sandwich ELISA optimization of Campath and HCA-4 concentrations. 
Concentrations of Campath at 10µg/mL or 20µg/mL plotted against concentrations 




bound to Campath at 20µg/mL, and a less intense signal compared to Campath at 
10µg/mL is generated as a result. Thus, adding a higher concentration of Campath is a 
waste of the reagent, as the higher concentration did not increase the amount of CD52g 
immobilized to the plate. Regardless of the Campath concentration, decreasing the 
concentration of primary antibody, decreased the signal generated. This was expected, as 
decreasing the concentration of primary antibody would result in fewer available epitopes 
to which the conjugate antibody could bind to. The optimal concentration of Campath 
used to coat all subsequent plates was 10µg/mL. The concentration of HCA-4 that could 
optimally detect CD52g immobilized by Campath (at 10µg/mL) was 100µg/mL. 
 
3.3 INDIRECT ELISA: OPTIMIZATION OF SEMINAL PLASMA DILUTION AND 
PRIMARY ANTIBODY CONCENTRATION  
 
Optimization of SP Concentration  
While the enhanced specificity of a sandwich ELISA made the format an excellent choice 
for detecting CD52g antibodies in sera, the technique required a 2 hour incubation of SP 
and varying quantities of Campath, which is a costly reagent. It was worth investigating 
whether CD52g could be detected via a less expensive and more expedient strategy, such 
as an indirect ELISA, without compromising the strength of the signal produced. Again, 
seminal plasma was used as the source of CD52g. To determine the optimal dilution of 
SP required to coat the microtiter plate of an indirect ELISA, three dilutions of SP were 





Optimization of Primary Antibody (HCA) Concentration 
HCA was serially diluted to determine the concentration that would allow for optimal 
detection of CD52g that was absorbed to the plate.   
 
Production of Assay Components 
SP was serially diluted in PBS (1:10, 1:20. 1:30) to produce three different coating 
solutions, each of which used to coat individuals wells in triplicate (200µL/well) on a 
single microtiter plate. The primary and conjugate antibody conditions were kept the 
same as in the previous experiment. Specifically, a 2-fold dilution series of HCA-4 was 
assayed and the conjugate antibody, rabbit anti-human IgG, was diluted 1:5000 in PBS. 
VRC01 (IgG1), a broadly neutralizing antibody against HIV-1, was used as an isotype 
control. VRC01 is of the same subclass as HCA-4, but is specific to the CD4 binding site 
of the glycoprotein, gp120, an HIV envelope protein. As seminal plasma is a complex, 
heterogenous mixture, it is possible that HCA-4 could bind to endogenous components of 
SP, other than CD52g. To gauge the degree to which this nonspecific binding occurred, 
VRC01 was assayed.   
 
Assay 
Three different dilutions of SP (1:10, 1:20. 1:30) and six different concentrations of 
HCA-4 were assayed on a single plate using the indirect ELISA procedure described in 




Figure 4. Indirect ELISA optimization of SP coating dilution and 
HCA-4 concentration. Dilutions of SP were coated to the plate and 
were plotted against concentrations of HCA-4 ranging from 100µg/mL 
to 0 µg/mL. Error bars represent standard deviation 




All three SP dilutions yielded signals with nearly the same intensity at each of the 
different concentrations of HCA. In other words, there was no decrease in signal intensity 
as the concentration of CD52g was decreased on the plate. Thus, the plate wells adsorbed 
a similar amount of CD52g regardless of the extent to which the SP was diluted. This 
implies that the capacity of the plastic microtiter plate to bind CD52g is finite and thus 
even if higher levels of CD52g (smaller dilutions) were assayed, no more antigen could 
possibly attach to the well surface. The isotype control, VRC01, generated a considerable 
signal when the SP coating was at a 1:10 dilution. In fact, the mean OD of the isotype 
control at a 1:10 dilution of SP was slightly higher than the signal produced from HCA-4 
at 100µg/mL, suggesting that the HCA-4 signal generated was unlikely to accurately 
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represent an interaction between HCA-4 and CD52g. However, it is possible that the 
intense signal generated by VRCO1 is simply an artifact and repeating the experiment 
would have elucidated the degree to which it was a false positive result. Nonetheless, the 
great variety of carbohydrates and proteins present in SP could allow for HCA-4 to bind 
non-specifically these molecules, if they contained similar epitopes to that recognized by 
HCA-4. The difference in the intensity of the signal generated by VRC01 versus HCA-4 
when SP was further diluted (1:20 and 1:30) suggested that diluting the SP minimized 
such background noise reactions, perhaps by simply decreasing the number of available 
biomolecules to which the primary antibody (HCA-4) and/or the isotype control could 
interact with. The SP dilution at 1:20 yielded a slightly higher signal than that of the SP 
dilution at 1:30, with only a negligible difference in the isotype control (VRC01) signal. 
Therefore, to optimally detect CD52g via an indirect ELISA, a SP dilution of 1:20 and 
HCA at 100µg/mL was deemed optimal.  
 
3.4 INDIRECT ELISA: OPTIMZATION OF SERA DILUTION 
Titration of Individual Positive and Negative Serum Samples  
Sera collected from 88 patients diagnosed with infertility and positive for ASA, as well 
as, sera from 11 healthy controls, negative for ASA, were available for assay 
development. Aliquots (100µL-200µL) of these samples were frozen at -80℃. Bronson et 
al. previously determined the incidence of antisperm antibodies (ASA) in each serum 
sample and the localization of bound, sera-derived ASA, on the sperm surface, via an 
immunobead test (IBT). As both the proper dilution of SP and optimal concentration of 
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the primary antibody, HCA-4, to detect CD52g, via an indirect ELISA, had been deduced 
(Figure 4), the assay protocol could be further modified to determine the concentration of 
CD52g antibodies present in each of the 88 serum samples positive for ASA. The dilution 
of sera required for such an assay was now determined by titrating the serum samples 
against a constant dilution of CD52g. There was a concern that activated complement 
components in sera could alter the measurement of CD52g antibodies in sera. For 
instance, active C1q could be retained on the plate and enable endogenous IgG 
antibodies, not specific to CD52g, to be immobilized in to the plate. C1q could also bind 
immune complexes in sera and potentially trap them within the ELISA system. The 
subsequent addition of the conjugate antibody would produce a falsely elevated OD 
value. In order to ascertain the degree of such interference, heat-inactivated human serum 
(HIHS) was assayed.  
 
Production of Assay Components  
A 1:20 dilution of SP was erroneously produced using sample diluent (which contains the 
surfactant Triton X-100) and served as the coating buffer. A two-fold dilution series 
(50µL/well) of each serum sample in sample diluent (1:20 to 1:640) was added to the 
ELISA plate after the blocking step. A single serum sample positive for ASA and a single 
serum sample negative for ASA were assayed. A set of antibody (HCA-4) standards were 





Figure 5. Indirect ELISA optimization of serum dilution. A serum 
sample positive for ASA and a serum sample negative for ASA were 
serially diluted and tested against a constant 1:20 dilution of SP. Heat-
inactivated human serum (HIHS) was assayed as an indication of the 
degree of complement interference in the assay. HCA-4 concentrations 
ranging from 100µg/mL to 0 µg/mL were used as a positive control. 
Error bars represent standard deviation.   
 
Assay 
An indirect ELISA was performed following the procedure described in section 3.1 






The depressed HCA-4 signal, as compared to that generated in the previous ELISAs 
(Figs. 3&4) was due to the erroneous dilution of SP into sample diluent (0.5% Triton X-
100) rather than PBS. The presence of Triton X-100 disrupted the hydrophobic 
interactions necessary for an optimal amount of CD52g to adsorb to the plate. Thus, in 
this assay, CD52g may only be present in minute quantities on the plate. The challenge in 
this study was to detect CD52g specific antibodies present in human sera. Titration of the 
serum sample negative for ASA fell within the range of the standard HCA-4 curve, 
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casting doubt on the negativity of the sample and the specificity of the assay. Though 
there was discrimination between the positive and negative ASA samples, it was entirely 
unclear to what degree CD52g-specfic antibodies were actually being detected. Titration 
of the negative serum sample and the heat-inactivated sample yielded absorbance values 
with nearly the same intensity. Thus, if CD52g antibodies were actually being detected in 
the assay, their detection in the negative serum sample was likely not mediated by active 
complement. Given that the HIHS was derived from an individual not diagnosed with 
infertility, it is possible that a baseline level of CD52g antibodies were measured in the 
HIHS and the negative serum samples. This would be analogous to previous research that 
found ASAs in the sera of both fertile and infertile individuals. This hypothesis is 
discussed further in section 3.16. However, it is also very possible that the measured 
absorbance of both the negative and positive sera was entirely a consequence of non-
specific binding of sera immunoglobins to the diverse array of SP components. With 
regard to the positive ASA serum sample, it is possible that the signal generated 
represents a genuine interaction between CD52g and CD52g antibodies. However, the 
physiochemical properties of sera, which can contribute to falsely elevated signals has 
not been accounted for. The preponderance of non-CD52g antibody binding substances, 
in human sera, and in seminal plasma, underscores the fact that both seminal plasma and 
human sera are diverse matrixes. Both are composed of immunoglobulins and other 
unsuspecting endogenous substances that could lead to an inaccurate measurement of 
CD52g antibodies. Therefore, this assay elucidated it would be necessary to determine 
the degree of background noise reactions in each individual sample, as such nonspecific 
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reactions could exceed the number of true CD52g-CD52Ab reactions. Though it was not 
possible to truly differentiate between positive and negative samples in this assay, as 
background noise reactions were not measured, a dilution of sera between 1:80 and 1:640 
was within the range of the HCA-4 standard curve and demonstrated a difference in 
signal intensity between the negative and positive samples. Therefore, a 1:100 dilution of 
sera was chosen as an appropriate starting dilution for subsequent assays.  
 
3.5 MODIFICATIONS TO THE ELISA PROTOCOL   
In a preemptive attempt to reduce the incidence of non-specific binding and enhance the 
sensitivity and strength of the signal generated, several aspects of the assay protocol were 
altered. 
 
Modification: Purifying IgG from Seminal Plasma  
Given that seminal plasma contains IgG antibodies, it was possible that these antibodies 
could absorb to the plate and upon addition of the conjugate antibody, (rabbit anti-human 
IgG) would bind the conjugate and generate a falsely elevated measure of CD52g 
antibodies (high background). To mitigate this, SP (1:20) was put into a Protein G 
Agarose column and the flow-through was collected and assayed. Protein G Agarose is 
composed of recombinant Protein G bound to agarose beads. Protein G binds 
preferentially to the Fc region of IgG thereby removing IgG from SP. The Thermo 





Modification: Addition and Incubation of Serum, Controls, and Standards  
The serum samples, HCA-4 standard and any controls were produced as described in 
section 3.1 but were added to the wells of a non-tissue cultured treated, V-bottom, 96 
well microtiter plate, and subsequently transferred, by multichannel pipette, to the coated 
and blocked ELISA plate. This method would minimize the time difference between 
addition of the first and last sample, and thereby ensure that the results of the assay were 
not affected by differences in incubation times. This method would also prevent the wells 
from drying out between the addition of each sample. The activity of assay reagents, 
particularly the HRP-conjugate, could be compromised if the wells dry out, weakening 
the signal generated. To account for variation in the antibody titer of each patient, it was 
important to have a wide enough range of dilutions to capture most of the patient titers. 
Therefore, highly concentrated HCA-4 (400µg/mL) was added to the assay standard. To 
strengthen the intensity of the signal, the plates were incubated overnight at 4℃ (rather 
than for two hours at 37℃) after addition of the test samples, the HCA-4 standard and 
any controls. The protocol then proceeded as described in section 3.1.   
 
3.6 INDIRECT VS SANDWICH ELISA: BACKGROUND NOISE REACTIONS AND 
PLATE VARIABILITY  
Background Noise Determination  
The same serum samples assayed in the previous ELISA (Figure 5) were again assayed 
using two different ELISA formats, a sandwich ELISA and an indirect ELISA. In this 
assay, the degree of background noise inherent in each serum sample was determined by 
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adding serum positive for ASA to wells that were blocked but that did not contain CD52g 
(PBS and not SP was added to these wells). The OD of the wells with and without 
antigen could then be compared. 
 
Negative Controls 
Blank wells, coated with either SP or capture antibody and blocked, but lacking serum 
and antibody conjugate were assayed to account for any variation in the OD due to the 
plate itself. Wells with immobilized CD52g and blocked but containing only the 
conjugate antibody and not serum were also assayed. High OD values measured in these 
wells would demonstrate nonspecific binding of conjugate antibodies, which should be 
prevented by the blocking buffer. Thus, these wells essentially measure the effectiveness 
of the blocking buffer in preventing binding of the secondary antibody.  
 
Indirect ELISA: Assessment of Well-to-Well Variation  
Two sets of HCA-4 standards were plated (in triplicate) to assess variation in the 
measured OD between wells across the plate; variation could occur as a consequence of 
poor technique (inaccurate pipetting, bubbles in wells, inconsistent washing), variable 
incubation times between wells, or inconsistences with reagents (insufficient vortexing, 





Sandwich ELISA: Confirmation of Campath Concentration and Assessment of Well-to-
Well Variation 
Two sets of HCA-4 standards were again plated (in triplicate) to assess any source of 
variation across the plate. The concentration of Campath (10µg/mL or 20µg/mL) used to 
coat the plates was repeated to confirm the results of previous experimentation (Figure 3).  
   
Production of Assay Components  
Serum was diluted 1:100 in sample diluent. All other reagents were diluted according to 
the protocol in section 3.1. 
 
Assay 
The sandwich and indirect ELISAs were performed following the protocol described in 
























The intensity of the signals generated with Campath at 10µg/mL, upon addition of higher 
concentrations of HCA-4, was slightly stronger, though not significantly so, from that 
generated when Campath was at 20 µg/mL. Thus, the lower concentration of Campath 
maximized signal intensity, while minimizing the amount of reagent required per assay.  
At lower concentrations of HCA-4 (6.25 µg/mL and 1.56 µg/mL) a depressed signal was 
generated in wells with Campath (10µg/mL) compared to those coated with the higher 
concentration of Campath (20µg/mL). This is likely the result of CD52g being bound in 
excess of HCA-4 when the wells were saturated with 10µg/mL of Campath. The more 
limited amount of CD52g bound to Campath at 20µg/mL was optimally detected by the 
smaller concentration of HCA-4. Therefore, the optimal concentration of Campath 
(10µg/mL) was confirmed. The HCA-4 standard demonstrated that there was little 
Figure 6. Background noise and plate variability in sandwich ELISA detection 
of CD52g antibodies in serum samples (1:100). Error bars represent standard 
deviation.   
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variation across the plate. As the concentration of HCA-4 decreased, so did the signal 
generated upon addition of the conjugate, in a consistent manner across the plate. If great 
disparities in the measured OD values existed between the replicates then accuracy of the 
data would have been negated. Thus, well to well variation was low. The background 
noise OD values obtained in the wells that lacked CD52g (i.e. lacked SP) were nearly as 
high as those obtained in wells with CD52g. Therefore, it was impossible to distinguish 
antigen-antibody reactions from non-specific reactions. The fact that the serum seemingly 
negative for ASA generated a signal with an intensity nearly equal to those of the highest 
concentration of HCA-4, and the wells measuring positive serum antibody reactions, 
further challenged the degree to which the ELISA was accurately measuring CD52g 
antibodies in the presence of other serum components. The lack of a signal in the blank 
control wells confirmed that the plastic of the ELISA plate and/or buffers (sample diluent 
or wash buffer) were not contributing to the measured absorbance values. However, the 
presence of a signal in the wells in which only the conjugate antibody was added suggest 
that blocking and/or washing was insufficient. The secondary antibody was binding to 
regions of the plate that were not adequately coated with BSA or could have bound to SP 
or sera components that were not effectivity removed from the system during the washing 
process. This assay evidenced the importance of measuring background noise in both the 






Figure 7. Background noise and plate variability in indirect ELISA 
detection of CD52g antibodies in serum samples (1:100). Error bars 




Similar to results of the sandwich ELISA method (Figure 6), the indirect ELISA 
demonstrated that variability across the plate was negligible, but background noise 
reactions were not. The replicates of the HCA-4 standards were consistent across the 
plate. In this assay, the background noise reactions actually exceeded the antibody-
antigen reactions measured in both the negative and positive ASA serum samples. 
Therefore, as in the sandwich ELISA, the false positive results are likely a consequence 
of non-specific reactions, the incidence of which needed to be reduced, in order for the 
assay’s data to be interpreted correctly. In the indirect ELISA, the most intense signal 
was generated from the background wells, in contrast to the sandwich ELISA, in which 
the OD value measured for the positive ASA serum was slightly greater than that of the 
background wells (Figure 6). The specificity of the sandwich ELISA, the fact that 
Campath captures CD52g and other seminal plasma components should be washed away, 
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may have slightly minimized the background noise derived from seminal plasma 
components. However, interference caused by sera immunoglobulins remained a distinct 
concern. Since both negative controls failed to generate a signal, it suggested that 
blocking was sufficient and that plate components and buffers used in the assay were not 
contributing to absorbance values. Methods to reduce the contribution of serum 
components to background noise reactions needed to be considered along with 
determination of background noise reactions in all serum samples both negative and 
positive. The sandwich ELISA remained the best strategy for detecting CD52g 
antibodies, as it allowed for more confidence in assessing the assay’s ability to detect 
CD52g specific antibodies as opposed to endogenous sera immunoglobulins binding non-
specifically to SP antigens.  
 
3.7 CONTINUED OPTIMZATION OF SERA DILUTION AND DILUENT  
 
Optimization of Sera Dilution and Diluent 
A simple method to attempt to reduce non-specific binding of antibodies in sera was to 
further dilute the sera. In doing this, the concentration of antibodies in sera would be 
reduced and would thereby limit the capacity of low affinity non-specific interactions to 
be maintained while favoring specific, higher affinity antigen-antibody interactions. 
Universal Assay Buffer (UAB), a commercial buffer developed for diluting serum for use 
in Luminex assays, was compared with sample diluent (PBS with 10% FBS and 0.5% 





Production of Assay Components  
Campath (10µg/mL) diluted in PBS was used to coat two microtiter plates. A 1:20 
dilution of SP was produced in sample diluent. A ten-fold dilution series (1:100 to 
1:1,000,000) of serum samples (50µL/well) diluted in sample diluent or UAB was 




Two sandwich ELISAs were conducted according to the protocol outlined in sections 3.1 
and 3.5  
 
 






Figure 8. Sandwich ELISA: series dilution of sera in sample diluent (PBS 
with 10% FBS and 0.5% Triton X-100  and background noise 
determination in the detection of CD52g antibodies in serum samples. 




Figure 9. Sandwich ELISA: series dilution of sera in universal assay 
buffer (UAB) and background noise determination in the detection 
of CD52g antibodies in serum samples. Error bars represent 
standard deviation.   
Analysis of the measured absorbance values via a one-way ANOVA and post-hoc 
analysis with Tukey’s test, determined that there was no significant difference in 
absorbance between the positive and negative serum samples in the presence of CD52g 
(p=0.406). Moreover, there was no significant difference in the mean OD of positive sera 
wells with and without CD52g (p=0.067). Such findings reinforced the supposition that 
non-specific antibody reactions and other undesirable phenomena were interfering with 
the measurement of CD52g specific antibodies. Thus, methods to ensure that the assay 
can differentiate between background noise reactions and true CD52g antibody reactions 
were paramount. There was a significant difference in absorbance between the negative 
serum sample and background noise (p=0.002, p< 0.05). It may be that further diluting 
the negative serum sample was more effective at reducing background as compared to the 
positive sample, due to inherent differences in the amount of endogenous antibody in 





In this sandwich ELISA, the positive and negative serum samples were diluted with UAB 
rather than sample diluent. Although there no significant difference in absorbance 
between the negative and positive serum samples, there was significant differences in the 
absorbance between positive and negative serum samples and background noise 
reactions. The higher OD values generated when the sera were diluted in sample diluent 
(Figure 8) are likely the result of more non-specific reactions, and not an indication that 
using sample diluent produced a more sensitive assay. In contrast, with the use of UAB, a 
1:10,000 dilution of sera still yielded a signal that that was significantly different from 
background noise reactions. Antibody-antigen reactions in both the positive and negative 
serum samples could be discriminated from background noise reactions for the first time. 
This suggested that the UAB was more effective than the combination of BSA and Triton 
X-100, in the sample diluent, at reducing non-specific binding of sera derived antibodies. 
It is possible that the UAB is composed of a more effective detergent, or a detergent at a 
higher concentration such that weak, non-specific antibody reactions could not withstand 
its effects. The UAB could contain other antibody binding substances that compete with 
endogenous human antibodies for binding to CD52g and thereby facilitate the binding of 
high affinity antibodies to CD52g. At a sera dilution between 1:1,000 and 1:10,000 the 
assay still produced a signal and background noise reactions were below the limit of 
detection, suggesting that a dilution in this range could sufficiently eliminated 
background noise. However, differentiating between samples positive and negative for 
ASA remained a challenge. It was possible that the serum sample positive for ASA and 
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the ELISA was accurately assessing the relative degree of CD52g antibodies between two 
patients.  
 
3.8 SANDWICH ELISA: ASSESSMENT OF BLOCKING AGENTS AND SERA 
DILUTIONS 
Optimization of Sera Dilution  
All of the previous ELISAs had been conducted using the same single positive and single 
negative serum sample. Since there was bound to be great variation in the degree of 
CD52g antibodies (and interfering substances) in sera from patient to patient, utilizing 
pooled samples would increase the yield of reactive CD52g antibodies assayed and could 
potentially help to discriminate between positive and negative serum samples. Highly 
dilute serum (1:10,000) was thought to be optimal, as higher dilutions would decrease the 
concentration of IgG in the serum and perhaps, thereby, decrease any non-specific 
reactions or deposition of sera IgG to the plate. Yet the high dilutions of serum would 
inevitably reduce the intensity of the signal generated by the assay. Previous 
experimentation, albeit with one patient’s serum sample (Figure 9), did show minimal 
background noise with an intense signal at a serum dilution of 1:1,000. Therefore, it was 
worth investigating whether a lower dilution of serum along with another blocking 
method, would enhance the intensity of the signal generated by the ELISA, while 
reducing background noise reactions. The only concern was that at a lower dilution it was 
very likely that the background noise reactions would exceed the real antigen-antibody 
reactions. This would then result in a misinformed conclusion. Nevertheless, to see if the 
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intensity of the measured OD values could be enhanced with a lower dilution of serum, 
without a corresponding increase in background noise, pooled serum samples were 
diluted either 1:1,000 or 1:10,000.  
 
Optimization of Blocking Agent 
Two common blocking agents, BSA, and non-fat dry milk, were assayed to determine if 
one was more effective at reducing background noise reactions.  
 
Production of Assay Components  
Pooled serum samples (50µL/well) were diluted 1:1,000 or 1:10,000 in UAB and 
assayed. The blocking buffer called for in the ELISA protocol consisted of PBS with 5% 
Fetal Bovine Serum (FBS). In this assay, the blocking agent previously used (BSA) was 
compared to that of PBS with 5% non-fat dry milk. All other components were produced 
according to the protocol in section 3.1. 
 
Assay 








Figure 10. Sandwich ELISA: Comparison of the effects of blocking 
agents and sera dilutions on background noise reduction. Error bars 
represent standard deviation.   
  




The combination of blocking agent and serum dilution that generated that highest 
measured OD value, with the least background noise for the pooled positive serum 
samples was the FBS/BSA block when the sera was diluted 1:10,000. This same 
combination of reagents was optimal for assaying the pooled negative serum samples as, 
it yielded the smallest signal with minimal background. Regardless of dilution, the FBS 
block was more effective at reducing background noise reactions from the serum 
samples. In fact, background noise was eliminated from the pooled negative serum 
diluted at 1:10,000. It is possible that the serum antibodies specific to milk proteins 
bound and generated an intense background noise signal. However, neither blocking 
agent was totally effective at eliminating background in the pooled positive sera. Both 
FBS and milk proteins were equally effective at preventing non-specific reactions of the 
conjugate antibody in blank wells-wells that contained no sera, as the measured OD 
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values in such wells were below the limit of detection. Repeating the assay to validate 
this result would be warranted. This corroborated the previous ELISAs (Figs. 8,9,11) in 
which there was no non-specific binding of the conjugate antibody to the wells of the 
plate, suggesting that the plate is optimally blocked, in terms of the ability of the 
conjugate to empty regions of the plate. However, the background noise is this assay is 
likely not a consequence of non-specific binding of the secondary antibody to the plate, 
but that of antibodies in the serum. The conjugate antibody might not be able to bind to 
the surface of the plate, but it could bind to sera IgG that is potentially bound to the plate. 
High dilutions of the sera that greatly reduce the total concentration of sera antibodies are 
probably more responsible for the reduction in background noise than the FBS. In other 
words, only at the proper dilution of serum will the blocking agent be effective at 
reducing the non-specific binding of serum to the plate. However, it is probable that even 
if the plate is optimally blocked, there is bound to still be interference or background 
noise derived from serum antibodies. With the ponderance of IgG antibodies in serum, it 
is inevitable that there will be some degree of hydrophobic binding of serum IgG to the 
plate. It is also possible strong protein-protein interactions between serum antibodies and 
antigens either derived from the serum or from assay reagents could interfere with the 
binding of CD52g antibodies to CD52g and give rise to false positive results. This is 







3.9 SANDWICH ELISA: ESTABLISHMENT OF NEGATIVE CONTROL SERA 
 
Screening Negative Sera for anti-CD52g Antibodies 
As there had been no clear, reproducible distinction in the level of CD52g antibodies 
between populations positive or negative for ASA (Figs 6-9), it was decided that a 
limited number of negative sera, which showed minimal background noise reactions and 
relatively low OD values, would act as negative controls in future sandwich ELISA 
assays.  
 
Production of Assay Components  
All eleven serum samples negative for ASA (50µl/well) were diluted in UAB (1:10,000) 
and assayed via a sandwich ELISA. A pooled serum sample positive for ASA was 
similarly diluted and assayed. All other components were produced as previously 
described in section 3.1 
 
Assay 









Figure 11. Sandwich ELISA: Screening of CD52g antibodies in serum 
samples determined to be negative for ASA via an immunobead assay. 
Error bars represent standard deviation.   
 











In all the negative serum samples, CD52g antibodies were potentially detected to varying 
degrees. However, there was a distinct difference in the absorbance values between 
negative and positive sera. Moreover, there were four serum samples in which 
background noise reactions were below the limit of detection (E1,E2,E6,E11). These 
samples were pooled and would act as negative controls in the remaining assays.  
 
3.10 SCREENING OF SERUM SAMPLES POSTIVE FOR ANTI-SPERM 
ANTIBODIES  
Assaying Positive ASA Sera For CD52g Antibodies  
Eighty-eight serum samples positive for anti-sperm antibodies were diluted 1:10,000 in 
UAB and assayed (50µL/well) against the pooled negative control serum (50µL/well).  
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Figure 12. Screening sera for CD52g antibodies. A total of 88 samples were 
screened. All serum samples were diluted in UAB at 1/10,000 and assayed via a 
sandwich ELISA. Error bars represent standard deviation.  
Production of Assay Components  
All other components were produced as previously described in section 3.1 
Assay 
A sandwich ELISA was conducted according to the protocol in section 3.1 and section 
3.5 
 












There was no significant difference in the level of CD52g antibodies in the serum 
samples positive for ASA as compared to negative controls. Background noise reactions 
continued to remain as just as high or exceed the measured OD values of the majority of 
the serum samples assayed and prevented the detection of CD52g antibodies via the 
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current ELISA. The degree to which diluting the serum in UAB reduced interference 
varied significantly depending on the serum sample.  
 
3.11 FUTHER OPTIMIZATION OF SAMPLE DILUENT  
Optimization of Sample Diluent  
As the serum samples assayed still demonstrated significant background noise reactions, 
likely due to low affinity antibodies in sera, it was thought that perhaps increasing the 
concentration of detergent in the sample diluent could have an inhibitory effect on non-
specific binding of sera immunoglobulins, perhaps to a greater extent than that of the 
UAB.  
 
Production of Assay Components 
Increasing concentrations of Triton X-100 were added to PBS with 10% FBS. Pooled 
positive and negative sera samples were diluted 1:10,000 in the sample diluent. 
 
Assay 
The sandwich ELISA protocol outlined in sections 3.1 and 3.5 was followed.  
 











Serum positive for ASA diluent in 8% Triton X-100 and 10% FBS in PBS was just as 
effective as the UAB in reducing background noise and allowed for an increase in the 
intensity of the measured OD value. Perhaps, increasing concentration of surfactant 
inhibited the rather weak interactions between sera immunoglobins and extraneous serum 
components or components of the ELISA, allowing for more numerous, high affinity 
interaction between CD52g specific antibodies to be maintained, and thereby generate a 
more intense signal. Any CD52g antibodies binding non-specifically to serum 
components, the ELISA plate, or Campath, would not be able to resist the activity of the 
more concentrated surfactant. Increasing the concentration TritonX-100 beyond 8% was 
excessive and the activity of the detergent may have competed with the ability of specific  
Figure 13. Sandwich ELISA detection of CD52g antibody 
levels and background noise reactions as a function of the 
sample diluent. Serum samples were diluted in UAB or 
sample diluent with increasing concentrations of the 
detergent Triton X-100 at 1/10,000. Error bars represent 
standard deviation.  
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CD52g antibodies to bind to CD52g. This experiment was repeated to confirm the 
concentration of Triton X-100 that would increase signal intensity, while minimizing 
background as much as possible. The results are shown below (Figure 14). 
 
Although there was no difference in the measured OD of the positive serum as a function 
of increasing concentration of Triton X-100, background noise reactions were 
significantly reduced when the positive sera was diluted in 2% Triton X-100 compared to 
8% Triton X-100. However, there was no statistically significant difference between the 
0.5% Triton X-100 and 2% Triton X-100 sera dilutions, in terms of signal intensity or 
background noise reduction for the positive serum. Diluting the negative serum in 2% 
Triton X-100 was no better than the 0.5% Triton X-100 at reducing background, but both 
concentrations generated a weaker signal than the 8% Triton X-100 solution. In terms of 
background noise derived from the negative sera, the measured OD values were 
Figure 14. Sandwich ELISA detection of CD52g antibody levels and 
background noise reactions as a function of the concentration of the 
detergent Triton X-100 in the sample diluent(PBS with 10% FBS). 
Serum samples were diluted in sample diluent at 1/10,000. Error bars 
represent standard deviation. 
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significantly reduced with the 2% Triton X-100 solution compared to both the 0.5% 
Triton X-100 and the 8% Triton X-100 solutions. Therefore, sample diluent with 2% 
Triton X-100 was used to dilute all subsequent serum.  
3.12 SCREENING AGGLUTINATING SERA FOR CD52G ANTIBODIES  
Agglutinating Samples for CD52g Antibodies 
Since anti-CD52g antibodies agglutinate sperm, the ASA sera were assayed for 
agglutination activity. Sera that were found to agglutinate sperm were retested for CD52g 
antibodies, as the 2% Triton X-100 was hypothesized to increase the intensity of the 
measured OD values while minimizing background noise reactions. 
 
Production of Assay Components  
Twenty-four serum samples that were found to agglutinate sperm, as well as negative 
controls, were diluted in PBS with 10% FBS and 2% Triton X-100. All other components 
were produced according to section 3.1 
 
Assay 





























Figure 15. Sandwich ELISA detection of CD52g antibody levels in sera found to 
agglutinate sperm. Graphed is the level of CD52g antibody upon subtracting the 
background OD values in antigen-uncoated wells from the OD values in antigen-
coated wells. Serum samples were diluted in sample diluent (PBS with 10% FBS 




Twenty-four serum samples that were positive for ASA and found to agglutinate sperm 
were retested after being diluted in 2% Triton X-100. Increasing the concentration of 
detergent in the sample diluent, decreased background depending on the serum assayed. 
An ANOVA revealed that of the 24 samples, 5 samples had measured OD values 
significantly different than that of the negative control (p> 0.05). CD52g antibodies were 
detected in the sera (21%) of infertility patients whose serum was found to agglutinate 
sperm. 
 
CHAPTER 4. DISCUSSION 
The current study suggests that CD52g antibodies are not readily detectable by 
ELISA in serum from patients with infertility. After extensive assay optimization, 
convincing anti-CD52g activity was detected in only 21% of patients with sperm 
agglutinating antibodies. This suggests that antisperm antibodies, in a majority of cases 
were not directed at CD52g sperm antigen. Although the data from this study are 
preliminary and need to be repeated, they support previous research which has 
demonstrated that CD52g antibodies agglutinate sperm and may thereby contribute to the 
pathogenesis of immune infertility.  
 A principle concern was natural autoantibodies (natural antibodies) and anti-
idiotypic antibodies in sera. Previous research has suggested that at least some ASA are 
natural autoantibodies-polyreactive antibodies against diverse, poorly defined antigens 
which have a relatively weak affinity for any particular antigen. Other research has 
emphasized the role that anti-idiotypic antibodies may play in binding to sperm antigens 
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and thereby mediating immune infertility. A challenge in trying to measure the 
concentration of CD52g antibodies, some of which may be natural autoantibodies or anti-
idiotypic antibodies, is that by their very nature, these antibodies react to a variety of 
antigens, not limited to sperm antigens, that are present in the sera of both diseased and 
control populations. Control populations negative for ASA via an immunobead test may 
be positive for CD52g antibodies in sera as measured by ELISA. Immunobead testing 
and sera ELISAs are detecting different types of ASAs. ASAs present in serum are 
directed against a variety of sperm or seminal plasma antigens, and using ELISA the 
specificity of such ASA can be deduced. ASA detected by immunobead assays are direct 
against antigens found on the surface of sperm. As CD52g is both soluble (in 
epididymosomes) and membrane bound, it is reasonable that sera negative for membrane 
bound sperm antibodies could still be positive for C52g antibodies as a consequence of a 
natural or idiotypic antibody response. Natural autoantibodies to CD52g may bind to 
immobilized CD52g in ELISA but such binding may be relatively weak. Such weakly 
reacting sera may have been negative in the immunobead testing because the binding was 
not sufficient to bind live motile sperm and therefore was not subsequently detected by 
beads coated with anti-human immunoglobulins. Thus, the positive signal from negative 
control sera, may not necessarily be a consequence of antibody inference or a defect in 
the assay.  
As discussed by previous researchers, it is unlikely that antibodies against one 
sperm antigen are responsible for all sperm agglutination or immobilization activity. 
Indeed, researchers have emphasized that antibody localization, concentration, and 
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isotype as well as the intrinsic functions of the target antigens altogether determine the 
degree to which ASA impair sperm functioning. As such, the ELISA developed in this 
study does not indicate the functionality of the antibodies that are being measured. 
CD52g antibodies may be one of several ASAs, each of which has its own unique 
biological function and which acts in affiliation with each other, and complement 
proteins, to impair sperm motility in vivo.    
Complicating matters is that natural autoantibodies and idiotypic antibodies to 
antigens other than CD52g could have interfered with the ability of the assay to 
accurately measure CD52g antibodies in sera. These antibodies could react with a variety 
of antigens either derived from the sera itself, or from assay reagents, and generate false 
positive reactions in both ASA positive and negative populations. Natural autoantibodies 
and idiotypic antibodies could both potentially bind to the capture antibody, Campath. 
Anti-idiotypic antibodies may actually mimic the binding of CD52g to Campath due to 
its mirror-image structure. By linking the capture antibody and the conjugate antibody, 
these antibodies would falsely elevate the level of CD52g antibodies detected in sera. 
Thus, by competing with CD52g specific antibodies, natural autoantibodies and idiotypic 
antibodies are likely one type of background noise reaction that confounded the results of 
the assay and, if not measured, could have precipitated the misinterpretation of those 
results. It is also possible that natural autoantibodies and idiotypic antibodies may 
interfere with the ELISA in a non-competitive way, such as absorbing to the plate. 
Approximately 80% of serum is composed of IgG, with normal adult serum levels of IgG 
in the range of 7-16 g/L [103]. However, the concentration of CD52g specific IgG is 
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serum is considerably lower, in the order of µg/mL. It is, perhaps, unavoidable that a 
degree of sera derived IgG will absorb to the plate and potentially bind the conjugate 
antibody or its enzyme (HRP). Antibodies in serum against complement components or 
circulating immune complexes could also potentially remain in the ELISA system if 
activated complement managed to absorb to the plate. Methods to mitigate interference 
caused by natural autoantibodies and idiotypic antibodies included diluting the serum and 
increasing the concentration of detergent the sera was diluted in. The success of these two 
strategies depended largely on the characteristics of the individual serum sample. Even 
after diluting 1:10,000 and/or diluting sera samples in 2% Triton X-100, intense 
background noise reactions remained just as high as measured antigen-antibody 
reactions, in the overwhelming majority of sera samples. Blocking the plate with BSA or 
milk proteins was also considered to reduce the absorption of serum antibodies and 
immune complexes to the plate. However, natural autoantibodies, or antibodies specific 
to BSA or milk proteins, present in the sera could have reacted with their target antigen 
and been a source of considerable background noise. Indeed, in wells devoid of CD52g, 
the addition of FBS and sera did yield a signal regardless of the sera dilution (Figure 10). 
A blocking agent devoid of such animal derivates may be required in order to more 
effectively reduce non-specific binding of sera components to the ELISA plate. Indeed, 
human anti-animal antibodies are reported to occur in 30-40% of patients [104]. These 
high affinity antibodies, raised against a specific animal immunoglobulin class, are most 
commonly anti-mouse antibodies but can also include rats, rabbits, and cattle [104]. As 
assay reagents were produced in, or derived, from these animals, anti-animal antibody in 
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sera could have potentially reacted not only with BSA in the sample diluent and blocking 
buffer but potentially with the capture antibody or the conjugate antibody. ASA are also 
known to cross-react with a variety of bacterial antigens including E.Coli, S.typhi, 
H.pylori, C.trachomatis, and U.urealyticum. If these bacterial antigens were present in 
sera, immune complexes could form, deposit on the plate, and be detected by the 
conjugate antibody, resulting in an over-estimation of the concentration of CD52g 
antibodies. On the other hand, bacterial antigens could compete with CD52g for 
antibody, and thereby result in the underestimation of the concentration of CD52g 
antibodies.   
A challenge in developing this assay was that there was a need to reduce the 
concentration of natural autoantibodies and idiotypic antibodies that inferenced with the 
assay-that bound non-specificity to ELISA reagents or components. Yet some of these 
natural autoantibodies and idiotypic antibodies may have actually bound CD52g and 
deciphering the exact target of natural autoantibodies and idiotypic antibodies in the 
ELISA was not possible. Therefore, in trying to reduce the extent of natural 
autoantibodies and idiotypic antibodies in sera the goal was that high affinity CD52g 
specific antibodies would be detected. However the concentration of natural 
autoantibodies and idiotypic antibodies is unique to each individual patient. In one 
individual, the concentration of these antibodies could be low, but have a relatively high 
affinity for an array of epitopes. Meanwhile, in another patient, the concentration of 
natural autoantibodies and idiotypic antibodies could be high but bear a relatively low 
affinity for target antigens [104]. This variability complicates determining the 
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concentration of blocking agent or detergent that should constitute the sample diluent or 
blocking buffer, in order to effectively reduce non-specific antibody binding in all serum 
samples. This fact, coupled with ineffective blocking, may explain why the strategies 
employed in this study were insufficient to overcome background noise reactions in the 
majority of the sera assayed. Future experimentation could involve assaying serum 
samples with a high degree of background and control serum on BSA or skimmed milk 
coated plates for IgG deposition. Efforts could also be undertaken to compare the ability 
of detergents like Triton X-100, purified BSA, or milk protein as buffer additives to 
reduce background noise reactions.   
In light of these confounding factors, to assay CD52g antibodies in human sera it 
was necessary to include wells not coated with Campath (i.e. containing no antigen) to 
determine the background noise reactions of each sample. Although there was no 
significant difference in anti CD52g levels in patients positive for ASA as opposed to 
controls, 21% of sera that agglutinated sperm was positive for CD52g antibodies in the 
sandwich ELISAs. In order to further prove the CD52g specificity of the antibodies, 
competition assays need to be performed using purified CD52g. Only a subset of the 
ASA positive sera from infertility patients demonstrated the capacity to agglutinate sperm 
suggesting that the presence of agglutinating antibodies is suggestive of, but not a 
definitive marker of immune infertility. Moreover, serum CD52g antibody levels may not 
accurately reflect the immunological situation in genital tract secretions. If the antisperm 
immune response originated in the genital tract mucosa, it is possible that antibody titers 
would be higher in genital tract secretions than in sera. Sera derived ASA may be largely 
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natural auto-antibodies and/or anti-idiotypic antibodies and thus have a variable affinity 
for CD52g. These antibodies may react to sperm antigens like CD52g but not necessarily 
mediate infertility. Direct evaluation of the relative abundance and titer of CD52g 
antibodies in the secretory fluid of reproductive tissues in men and women would more 
accurately reveal the role in which CD52g antibodies play in agglutinating sperm in vivo. 
Yet, given that a fraction of agglutinating sera was positive for CD52g, it does support 
the hypothesis that the effectiveness of sperm movement is influenced by antibodies 
bound sperm surface antigens like CD52g.  
Even though the ability of the ELISA in this study to detect CD52g antibodies 
was limited, the importance of ASAs in mediating immune infertility should not be 
underestimated. Among the varied conditions that might underly the pathophysiology of 
unexplained infertility, alterations in sperm motility due to immunological reactions are 
significant. Treatment of ASA mediated infertility relies on ARTs, of which 
intracytoplasmic sperm injection (ICSI) has been the most successful [51]. Progress in 
understanding and treating infertility that arises as a consequence of auto or iso-immunity 
has been feasible, largely through studying individual candidate antigens like CD52g. 
Such research has enabled the discovery of new mechanisms and paradigms of immune 
modulation that are indispensable to the proper functioning and health of the human 
reproductive tract.  
Moreover, highly specific ASAs, raised against antigens that are involved in 
sperm functioning, may be effective immunocontraceptive agents. Development of a 
contraceptive device (a vaginal film or intravaginal ring) that delivers HCA, as well as 
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monoclonal antibodies to HIV and HSV, into the cervicovaginal mucosa is currently in 
progress by researchers in the Anderson Lab. This novel contraceptive relies on passive 
immunization with cost-sensitive, humanized monoclonal antibodies, that are engineered 
in the Nicotiana plant and its development is an exciting proposition. Major global issues, 
such as migration, climate change, population growth and ageing, gender equality, child 
care, and medical ethics, are indelibly linked to reproduction, specifically, when and how 
reproduction should happen. In this milieu, an effective dual purpose 
immunocontraceptive, that both prevents unintended pregnancy and STI transmission, 
would be invaluable. Such a novel technology has the potential to become a highly 
effective contraceptive method and, simultaneously, could improve the acceptability of, 
and adherence to, STI prevention and control efforts, and furthermore, to reduce the 
stigma surrounding such endeavors. These benefits elucidate that understanding the basic 
biology of both fertilization and individual sexually transmitted pathogens, in the broader 
context of the immune environment in which they exist, is paramount to developing 
preventative healthcare measures that would improve the reproductive health and 
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